John Stein
Dyslexia

Phil Cowen
Treatment of Major Depression: Beyond Generalised Serotonin Potentiation

Louis Lemieux
EEG, FMRI and Their Combination in the Study of Epilepsy
APO-go: treatment for PREDICTABLE symptoms of Parkinson’s disease

Use APO-go Pen early in treatment plan for rapid reversal of impending “offs”. Simple, easy to use sc injection

Positive NICE review: “Intermittent apomorphine injections may be used to reduce off time in people with PD with severe motor complications.”

TIME TO SWITCH THEIR OFFS TO PARKINSON’S

APO-go Ampoules: 05928/0020 APO-go Pens: 05928/0021 APO-go Pre-filled Syringes contain apomorphine hydrochloride, 10mg/ml, as follows: 10mg in 1ml – basic NHS cost £37.86 per carton of 5 ampoules. 50mg in 5ml – basic NHS cost £145.00 per carton of 5 ampoules. APO-go pens (disposable multiple dosage injector system) contain apomorphine hydrochloride 10mg/ml, as follows: 30mg in 3ml – basic NHS cost £123.91 per carton of 5 pens. APO-go Pre-filled Syringes contain apomorphine hydrochloride, 5mg/ml, as follows: 50mg in 10ml – basic NHS cost £73.11 per carton of 5 syringes. Marketing Authorisation Numbers: APO-go Ampoules: 05928/0020 APO-go Pens: 05928/0021 APO-go Pre-filled Syringes: 03926/0025 Legal Category: POM. Date of Last Revision: February 2006. For further information please contact: Britannia Pharmaceuticals Limited 41-51 Brighton Road, Redhill, Surrey RH1 6YS

www.apomorphine.co.uk

A Bridged Prescribing Information

Consult Summary of Product Characteristics before prescribing. Use The treatment of disabling motor fluctuations (“on-off” phenomena) in patients with Parkinson’s disease which persist despite individually titrated treatment with levodopa (with a peripheral decarboxylase inhibitor) and/or other dopamine agonists. Dosage and administration Apomorphine hydrochloride is administered subcutaneously either as an intermittent bolus injection or by continuous subcutaneous infusion. Its rapid onset (5-10 mins) and duration of action (about 1 hour) may prevent an “off” episode which is refractory to other treatments. Hospital admission under appropriate specialist supervision is necessary during patient selection and when establishing a patient’s therapeutic regime. Please refer to the Summary of Product Characteristics for full details before initiating therapy. Treatment with domperidone (typical dosage 20mg three times a day) before and during apomorphine HCI therapy is essential. The optimal dosage of apomorphine HCI has to be determined on an individual patient basis; individual bolus injections should not exceed 10mg and the total daily dose should not exceed 100mg. Contraindications Children and adolescents (up to 18 years of age) are not recommended for use in women of child-bearing potential or in nursing mothers. Interactions Patients should be monitored for potential interactions during initial stages of apomorphine therapy. Particular caution should be given when apomorphine HCI is used with other medications that have a narrow therapeutic window. It should be noted that there is potential for interaction with neuroleptic and antihypertensive agents. Precautions Use with caution in patients with renal, pulmonary or cardiovascular disease, or who are prone to nausea and vomiting. Extra caution is recommended during initiation of therapy in elderly and/or debilitated patients. Since apomorphine may produce hypotension, care should be exercised in patients with cardiac disease or who are taking vasoactive drugs, particularly when pre-existing postural hypotension is present. Neuropsychiatric disturbances are common in Parkinsonian patients. APO-go should be used with special caution in these patients. Apomorphine has been associated with somnolence, and other dopamine agonists can be associated with sudden sleep onset episodes, particularly in patients with Parkinson’s disease. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with apomorphine. Haematology tests should be undertaken at regular intervals as with levodopa when given concomitantly with apomorphine. Side Effects Local induration and nodules (usually asymptomatic) often develop at subcutaneous site of injection leading to areas of erythema, tenderness, induration, and (rarely) ulceration. Pruritus may occur at the site of injection. Drug-induced dyskinesias during “on” periods can be severe, and in a few patients may result in cessation of therapy. Postural hypotension is seen infrequently and is usually transient. Transient sedation following each dose of apomorphine may occur at the start of therapy, but this usually resolves after a few weeks of treatment. Nausea and vomiting may occur, particularly when APO-go treatment is initiated, usually as a result of the omission of domperidone. Transient mild confusion and visual hallucinations have occurred during apomorphine therapy, and neuropsychiatric disturbances may be exacerbated by apomorphine. The use of apomorphine HCI in conjunction with levodopa treatment may cause Coombs’ positive haemolytic anaemia. Eosinophilia has occurred in only a few patients during treatment with apomorphine HCI. Apomorphine is associated with somnolence. Breathing difficulties have been reported. Prescribers should consult the Summary of Product Characteristics in relation to other side effects. Presentation and Basic NHS Cost: APO-go ampoules contain apomorphine hydrochloride, 10mg/ml, as follows: 10mg in 1ml – basic NHS cost £37.86 per carton of 5 ampoules. 50mg in 5ml – basic NHS cost £145.00 per carton of 5 ampoules. APO-go pens (disposable multiple dosage injector system) contain apomorphine hydrochloride 10mg/ml, as follows: 30mg in 3ml – basic NHS cost £123.91 per carton of 5 pens. APO-go Pre-filled Syringes contain apomorphine hydrochloride, 5mg/ml, as follows: 50mg in 10ml – basic NHS cost £73.11 per carton of 5 syringes. Marketing Authorisation Numbers: APO-go Ampoules: 05928/0020 APO-go Pens: 05928/0021 APO-go Pre-filled Syringes: 03926/0025 Legal Category: POM. Date of Last Revision: February 2006. For further information please contact: Britannia Pharmaceuticals Limited 41-51 Brighton Road, Redhill, Surrey RH1 6YS

Information about adverse event reporting can be found at www.yellowcard.gov.uk Adverse events should also be reported to Medical Information at Britannia at the above address or telephone: 01737 773241 or e-mail drugsafety@forumgroup.co.uk
John Stein argues the case for dyslexia being a distinct neurological entity with a plethora of data to support its diagnosis and a rationale for how to treat it. This is a clear, thought provoking account by an acknowledged expert in this area and will be of great interest to neurologists and neuroscientists alike.

Simon Hammans reviews the approach to patients with mitochondrial disease in this supremely comprehensive and comprehensible account of this group of disorders. Simon, who worked with the late Anita Harding when the field was in its infancy, uses that perspective to distil the critical issues that are of value clinically as well as of interest scientifically.

Depression is common and its aetiology and treatment varied and complex. Professor Philip Cowan in his review takes us through the serotonin system and its fourteen different receptors to give us a clear account on the way in which 5HT could be best manipulated for maximal efficacy and for treating this condition with minimal side effects.

The origins of neuropathology can be traced back to Herophilus of Chalcedon in Greece around 300 years BC, according to Roy Weller in his article entitled “Neuropathology in Context”. Roy, who initially edited our neuropathology series, takes us through the history of this discipline and includes a discussion of its current standing and future position in neurological practice.

Katherine Symons in her article in the rehabilitation section discusses what happens with standing up patients with minimal conscious states or the vegetative state in terms of their behavioural capabilities. She comments that “this study demonstrates that simple interventions can improve the quality of life” and includes a discussion of its current standing and future position in neurological practice.

The management of chronic migraine, often in the context of analgesia abuse, is enough to induce a headache in all but the most robust of neurologists. It is therefore very useful to have Paul Shanahan and Manjit Matharu take us through their approach to this problem and how best to manage such patients in our sponsored Drugs in Neurology feature.

Dinesh Nayak and Kurupath Radhakrishnan, in their fascinating account on epilepsy in India, begin with the sobering fact that if all cases of epilepsy were seen by neurologists in this country then each neurologist would have to care for about 5,000 people with this condition! However, given that most of the population live in rural areas (away from tertiary centres and neurologists) then this is not the case but consequently they are seen by non-specialists who tend to favour expensive sub-therapeutic polypharmacy. This, coupled to the social stigma of having epilepsy (especially if you are a woman), makes management of this condition particularly difficult, when the only drug free of cost to patients is phenobarbital.

In the neurophysiology series, Professor Louis Lemieux explores the potential of EEG coupled to fMRI in the assessment of epilepsy. This novel technique has now developed to the point that interesting data is emerging which suggests it can provide more information on the origin of focal seizures and so could become a more mainline tool in the assessment of epilepsy patients in the future.

Andrew Larner in the fourth of his series on headache concentrates on its descriptions in the ancient world. In the course of his typically illuminating discussions he informs us that “wisdom is born of headache by way of unsafe sex” as well as revealing that Aristotle felt “that those with lousy heads are “less than ordinarily troubled with headache’.”

We have our usual regular items including journal, book and conference reviews, and don’t forget our website.
Editorial board and contributors

Roger Barker is co-editor of ACNR, and is Honorary Consultant in Neurology at The Cambridge Centre for Brain Repair. His main area of research is into neurodegenerative and movement disorders, in particular Parkinson’s and Huntington’s disease. He is also the University lecturer in Neurology at Cambridge where he continues to develop his clinical research into these diseases along with his basic research into brain repair using neural transplants.

Alasdair Coles is co-editor of ACNR. He has recently been appointed to the new position of University Lecturer in Neurommunology at Cambridge University. He works on experimental immunological therapies in multiple sclerosis.

Stephen Kirker is the editor of the Rehabilitation Section of ACNR and Consultant in Rehabilitation Medicine in Addenbrooke’s NHS Trust, Cambridge. He trained in neurology in Dublin, London and Edinburgh before moving to rehabilitation in Cambridge and Norwich. His main research has been into postural responses after stroke. His particular interests are in prosthetics, orthotics, gait training and neurorehabilitation.

David J Burt is the editor of our Conference News Section and is Professor in Movement Disorder Neurology & Honorary Consultant, Newcastle General Hospital. He runs Movement Disorders clinics in Newcastle-upon-Tyne. Research interests include progressive supranuclear palsy and dementia with Lewy bodies. He is also involved in several drugs studies for Parkinson’s Disease.

Andrew Larner is the editor of our Book Review Section. He is a Consultant Neurologist at the Walton Centre for Neurology and Neurosurgery in Liverpool, with a particular interest in dementia and cognitive disorders. He is also an Honorary Apothecaries’ Lecturer in the History of Medicine at the University of Liverpool.

Alastair Wilkins is our Case Report Co-ordinator. He is Senior Lecturer in Neurology and Consultant Neurologist, University of Bristol. He trained in Neurology in Cambridge, Norwich and London. His research interests are the basic science of axon degeneration and developing treatments for progressive multiple sclerosis.

Nicki Cohen is ACNR’s Neuropathology Editor. She is a Specialist Registrar in Neuropathology at Southampton and has a DPhil in Neuroscience. She is Chair of the Trainee’s Advisory Committee at the Royal College of Pathologists and Neuropathology trainee representative. Her research interests lie in CNS stem cell biology, and the brain’s response to injury.

Peter Whitfield is ACNR’s Neuurosurgery Editor. He is a Consultant Neurosurgeon at the South West Neurosurgery Centre, Plymouth. His clinical interests are wide including neurovascular conditions, head injury, stereotactic radiosurgery, image guided tumour surgery and lumbar microdiscectomy. He is an examiner for the MRCS and is a member of the SAC in neurosurgery.

International editorial liaison committee

See the website for additional Conference Reports:
Community Rehabilitation Network Conference, September 2007
Joint Indian Academy of Neurology/ABN, October 2007
British Society of Rehabilitation Medicine Winter Meeting, November 2007
PREVIEW: European Neurological Society 20th Annual Meeting, June 2008
excreted by active tubular secretion could reduce the renal clearance of the metabolite. Levetiracetam
of phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin or primidone. Drugs
other pyrrolidone derivatives or excipients. (For full dosage recommendations see SPC.)
increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.
be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15 minute infusion.
kg or more:
Monotherapy (adults and adolescents from 16 years):
for primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic
for myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy and
for partial onset seizures with or without secondary generalisation in adults and children from 4 years of age,
consideration by patients on a controlled sodium diet.
Active Ingredient:
KEPPRA® 100 mg/ml concentrate for solution for infusion
KEPPRA® 100 mg/ml oral solution
(Please consult the Summary of Product Characteristics (SPC) before prescribing.)
Infusion:
Uses:
Infusion:
Uses:
No dose adjustment with mild to
moderate hepatic impairment. With severe hepatic impairment (creatinine clearance <70ml/min) a 50%
reduction of the daily maintenance dose is recommended, as the creatinine clearance may underestimate the
renal insufficiency. Contraindications, Warnings etc. Contraindications: Hypersensitivity to levetiracetam,
other pyrrolidone derivatives or excipients. Precautions: If discontinuing treatment reduce dose gradually as
adjunctive therapy:  Adults and adolescents older than 12 years or weighing 50
Infusion:
Marketing Authorisation Numbers: 250 mg x 60 tabs: EU/1/00/146/004. 500 mg x 60 tabs: EU/1/00/146/10, 750 mg x 60 tabs: EU/1/00/146/14. 1,000 mg x 60 tabs: EU/1/00/146/24, 250 mg x 120 tabs: EU/1/00/146/25, 500 mg x 120 tabs: EU/1/00/146/35, 750 mg x 120 tabs: EU/1/00/146/36, 1,000 mg x 120 tabs: EU/1/00/146/37, 250 mg x 60 x 2 cards: EU/1/00/146/38, 500 mg x 60 x 2 cards: EU/1/00/146/39, 750 mg x 60 x 2 cards: EU/1/00/146/40, 1,000 mg x 60 x 2 cards: EU/1/00/146/41, 500 mg x 120 x 2 cards: EU/1/00/146/42. Solution x 300 ml: EU/1/146/027, Infusion (500 mg/5 ml) x 10 vials: £135.00. 250 mg x 60 tabs: £29.70. 500 mg x 60 tabs: £52.30. 750 mg x 60 tabs: £89.10. 1,000 mg x 60 tabs: £101.10. Solution x 300 ml: £71.00, Infusion (500 mg/5 ml) x 10 vials: £135.00. Name and Address of PL Holder: UCB S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium. Further information is available from: UCB Pharma Ltd., 108 Bath Road, Slough, Berkshire, SL1 3WE. Tel: 01753 534655. Fax: 01753 536632. Email: medicalinformationuk@ucb-group.com
Information about adverse event reporting can be found at www.yellowcard.gov.uk and adverse events should also be reported to UCB Pharma Ltd.

© 2007 UCB Pharma Ltd. © Keppra is a registered trade-mark of UCB Pharma Ltd. Printed in the UK. Date of preparation: November 2007. 01K77P12a

I'm going to win.
One AED, many lives
Dyslexia

The word dyslexia comes from the Greek, ‘disordered words’; it was coined by an ophthalmologist, Berlin, in 1887 to describe patients who had lost the ability to read due to a stroke dividing visual processing from language areas in the left hemisphere. We would now call this ‘acquired dyslexia’. Acquired dyslexia can take many forms depending on the precise areas lesioned. The features described separately below are combined to greater or lesser extents in most patients; ‘pure’ examples are extremely rare because strokes do not respect functional borders in the brain.

Both acquired and developmental dyslexias are most easily understood by reference to the two main routes by which we read words. The phonological or ‘sublexical’ route converts seen letters into their sounds. This process is essential for children reading new words and even experienced readers reading words they’ve never seen before, such as made up nonsense words like ‘tegwo’. We can read this word by translating it into letters into sounds, even though it has no meaning.

The second route to reading is the visual, semantic or ‘lexical’ route, where visual forms of words is recognised, hence their meaning is understood very quickly, because slow translation of the separate letters into their sounds is not required. This enables familiar and irregular words to be read quickly.

‘Phonological’ acquired dyslexia is when the patient’s sublexical, phonological route is most affected. He will have particular problems with letter to sound translation; and will not be able to read nonsense words like tegwo at all; because he has never seen them before, they are not represented in his visual lexicon. Hence he cannot use the other visual route for reading which may still be intact. This kind of acquired dyslexia occurs when the stroke involves the left supramarginal gyrus and also it is often combined with Broca’s motor dyspraxia when the left inferior frontal gyrus is damaged.

Visual, ‘letter by letter’ or ‘surface’ varieties of acquired dyslexia are seen when the alternative visual lexical reading route is damaged. Here the patients have particular difficulties with reading irregular words, such as ‘yacht’ or ‘bough’, where the letter sounds give little help to its pronunciation and the visual form of the word has to be learnt as a whole in order to read it correctly. Phonological ‘regularisation errors’ are therefore common, whereby the patient has to sound out each letter in the word, bough, and perhaps read it as ‘bog’. The most common site for lesions causing visual acquired dyslexia is in the ‘visual word form area’ that is situated in the anterior part of the left fusiform gyrus on the under surface of the occipito-temporal junction.

The third main kind of acquired dyslexia, ‘deep’ dyslexia, is when the patient’s misreading is semantically related, eg ‘ship’ is read as ‘boat’; the misreading has only a similar meaning, with no visual/orthographic or phonological resemblance to the target word. This occurs when there is partial disconnection between the semantic store of word meanings and their visual/orthographic and phonological representations, again often following lesions in the left angular gyrus. Normally when reading, both these are activated so that the word retrieved can be checked for accuracy against its phonological and orthographic forms.

Developmental Dyslexia

Deep acquired dyslexia is the most interesting kind from a theoretical linguistic point of view. But semantic errors of this kind are seen less often in ‘developmental’ dyslexia because this occurs in children learning to read, before they have acquired many visual or detailed phonemic representations of words. However phonological and visual versions of developmental dyslexia are frequently found, which is why considering acquired, is helpful for understanding developmental, dyslexia.

Developmental dyslexia (hereafter called simply ‘dyslexia’) is much more common than acquired. It affects perhaps 10% of all children, particularly boys, and is a potent source of individual and family misery. These children with normal or high intelligence unexpectedly find it very difficult to learn to read despite normal schooling and other opportunity. Most neurologists now view this condition as a neurodevelopmental syndrome, because its effects are not confined to reading, but instead reveal more fundamental underlying sensory, motor and attentional features. However, there is still fierce debate. Many psychologists still take the view that dyslexia is a specifically linguistic phonological condition without more basic underlying neurological causes.

Aetiology

The neurological case rests on many kinds of evidence: genetic, neuropsychological, functional imaging, physiological and psychophysiological and behavioural. First dyslexia has a strong genetic basis. Comparing diphagotic and monozygotic twins has shown that 60% of the variability in dyslexics’ reading can be attributed to the particular alleles they have inherited. Recent high resolution linkage studies have identified at least 6 chromosomal sites associated with reading difficulties. None seem to make any distinction between visual or phonological problems. Recently 4 genes, ROBO1, KIAA 0319, DYX1C1 and DCDC2 have attracted particular interest because they have all been implicated in the way in which neuronal migration is controlled early in brain development and with how new connections are formed later in development. For example, using RNA interference techniques, KIAA 0319 has been shown to provide essential surface active signals that control neuronal migration from the germinial ventricular plate up the radial glia to form the 6 layers of the mature cerebral cortex. However the slight underexpression of this gene that has been found in dyslexics is probably balanced by slightly increased expression of other genes that may explain the talents in areas other than reading that many dyslexics demonstrate.

The few dyslexic brains that have been examined in detail neuropsychologically have confirmed that they contain many sites of mild mismigration of neurones, that must have occurred in utero early in brain development. They show surface ‘ectopias’ which are small (c. 1 mm) outgrowths beyond the cortical surface where large migrating neurones seem to have failed to observe stop signals at the surface. These ectopias are particularly common in the homotypical association areas that form the language network in the left hemisphere. They are associated with disorganised connectivity of these neurones not only in the cortex immediately below them but also in the homotopic areas connected to them via the corpus callosum in the opposite right hemisphere.

In addition mild abnormalities have been detected in subcortical structures. For example the large neurones that should be confined to the magnocellular layers of the main visual relay in the thalamus, the lateral geniculate nucleus, were found to be 30% smaller and more disorganised than in control brains. Again they seem to have failed to observe stop signals, so that they had infiltrated the parvocellular layers of the LGN. Likewise in the left medial geniculate (auditory relay) nucleus of the thalamus the neurones were found to be smaller and more disorganised in control brains. To summarise the neuropsychological findings, large, ‘magnocellular’ neurones in both subcortical and cortical structures tend to be mildly abnormal and disor-
rganised in dyslexic brains. But it must be admitted that only a small number of dyslexic brains have been examined in this detail and these could have been exceptional.

However recent functional imaging studies in live subjects have corroborated this neuropathological story to a large extent. Figure 1 shows that the same areas that showed ectopias in the language network in the left hemisphere, namely the left anterior fusiform, angular and supramarginal and inferior frontal gyri, are found to be less activated when dyslexics read compared with good readers, whereas, perhaps in compensation, language area homologues in the right hemisphere together with the left middle frontal gyrus seem to be relatively overactive in dyslexics.

Figure 1

Neurophysiological studies have shown that visual, auditory and language related event related potentials are slower and smaller in many dyslexics, providing further evidence that dyslexia may be due to mild abnormalities in the overall development of the brain. But this conclusion is still hotly disputed because not all dyslexics show them. So they have been dismissed as 'epiphenomena' and not causal. But such thinking exhibits the logical fallacy known as the 'undistributed middle' — like saying that because not all diabetics suffer eye problems, eye problems are never caused by diabetes.

A fifth strand of evidence is behavioural. Developmental dyslexics have difficulty with reading of course. Although they make both visual and phonological errors most have the most trouble with splitting down the sounds of words into their constituent phonemes, so, like phonological acquired dyslexics, they make more errors trying to read nonsense words. They also tend to have poor short term phonological memory; so that they are also poor at repeating nonsense words read out to them. Others are more like visual acquired dyslexics; they have particular problems with reading irregular words, making characteristic visual errors such as continuing to confuse bs and ds and misreading god for dog or was for saw.

However in addition all developmental dyslexics are characterised by a variety of non-reading problems. They often report other members of the family who were affected. During development they may have been late crawlers or walkers, failed to learn to ride a bicycle easily and been generally clumsy. They tend to have difficulty distinguishing their left from their right sides. They usually have big problems with recalling a string of digits read out to them, particularly if they are asked to repeat them backwards. They tend to have difficulty with focusing attention and concentration, so that they are slow at reading out a simple list of digits, or naming a sequence of pictures, or reciting the days of the week or months of the year in the right order. None of these features are particularly dependent upon reading experience; hence they suggest that dyslexics tend to have a general problem with rapid linear sequencing, again suggesting a more fundamental neurological causation and casting doubt on a purely linguistic explanation.

This doubt is reinforced by the large number of studies that have shown low level sensory anomalies in dyslexics. Many have reduced visual sensitivity to flickering coarse black and white stripes, ie they have lowered contrast sensitivity to low spatial and high temporal frequency gratings. In line with their histological magnocellular abnormalities this is the hallmark of a selective impairment of the visual magnocellular system. This hypothesis that dyslexics have slightly impaired visual magnocellular function has been supported by numerous studies that have demonstrated that many dyslexics have reduced visual motion sensitivity, since this is mainly mediated by the visual magnocellular system. Likewise dyslexics show impaired auditory sensitivity to changes in the frequency and amplitude of simple acoustic stimuli; identifying these is thought to be carried out mainly by large neurones in the auditory system. Since these temporal changes mediate our ability to distinguish between the different sounds of letters, this is further evidence that dyslexics may have mild impairments in basic sensory processing that underlie their phonological reading problems. Again however, since not all dyslexics can be shown to have these impairments, it is vigorously argued that their basic problem is not sensory but at a higher phonological level. Nevertheless it is likely that many psychophysical tests lack the sensitivity required to detect the mild deficits characterising most dyslexics, but that together these slight auditory and visual deficits compound to make it difficult for them to learn to read.

Diagnosis

It is not surprising, given the amount of disagreement about its aetiology, that there is little agreement about how to identify developmental dyslexia reliably. Its hallmark is difficulty with reading, despite normal intelligence. But there after agreement ends. Those who believe that a linguistic phonological deficit is paramount argue that it is only necessary to demonstrate this to diagnose dyslexia. Yet children of low average intelligence experience the same kinds of difficulties with acquiring the phonological skills required for reading. So an influential body of opinion has concluded that there is no real difference between dyslexia and poor reading due to low intelligence, often known as ‘garden variety reading difficulty’. The logical conclusion to all this is that there is no such thing as specific reading difficulty or developmental dyslexia.

However this argument ignores the genetic, neurological and physiological evidence that dyslexia is a neurological syndrome. We can argue from this point of view that dyslexia should be diagnosed whenever there is a discrepancy between reading performance and general intelligence in the presence of many of the non-reading symptoms discussed above, such as family histo-
Treatment of Major Depression: Beyond Generalised Serotonin Potentiation

Increasing recognition of the burden of disability associated with recurrent depression led the authors of a recent article in the *Lancet* to conclude that worldwide, depression produces greater overall health impairment than diseases such as angina, arthritis, asthma and diabetes. Part of the reason for the substantial impact of depression on global health burden is its high lifetime prevalence (somewhere between 10-20%). Furthermore, patients with angina, arthritis, asthma and diabetes have a greatly increased risk of experiencing comorbid depression with correspondingly greater health and social disabilities. Indeed depression itself has been linked to an increased risk of a number of medical conditions such as cardiovascular disease and obesity.1

**Treatment of depression**

One of the reasons for the large health burden of depression is that community surveys suggest that only a minority of patients receive effective treatment with psychotherapy and antidepressants. Generic selective serotonin re-uptake inhibitors (SSRIs) such as fluoxetine and citalopram are recommended as first line treatment of moderate depression by the National Institute for Clinical Excellence. However, a recent large investigation in the United States (the STAR*D study) which assessed the response of over 2500 depressed patients to first line treatment with citalopram found that only about one third reached symptomatic remission.1 In clinical terms, remission means being almost completely free of depressive symptoms and it is an important endpoint because patients who reach this goal show better social and occupation function and have a greater chance of staying well than those with lesser degrees of improvement.2

As well as limited efficacy, SSRIs also have a number of adverse effects which limit their acceptability. Early in treatment patients can experience nausea, agitation and insomnia while later problems include sexual dysfunction and persistent sweating. A more recently described problem is an increased risk of gastro-intestinal (GI) bleeding, possibly because SSRIs inhibit the function of blood platelets through lowering platelet serotonin levels. When SSRIs are used as a sole therapy the risk of significant GI bleeding is increased about threefold but in combination with non-steroidal anti-inflammatory drugs (NSAIDS) the risk is much greater (about twofold) and prophylaxis with gastro-protective agents has been recommended.3

**Pharmacology of SSRIs**

The key pharmacological action of SSRIs is confined to blockade of the re-uptake of serotonin (5-HT) into pre-synaptic 5-HT nerve terminals. This increases the availability of serotonin in the synapse and produces a general activation of all post-synaptic serotonin receptors. Research over the last two decades has shown that serotonin receptors exist in multiple subtypes that have distinct biochemical and functional properties. The identification of these receptor subtypes and the development of selective ligands for them is currently a focus of intense activity in academic and industrial research.

At present researchers have described four main families of 5-HT receptors (5-HT1-4) and some of the families have themselves been subdivided into further receptor subtypes; at present at least 14 pharmacologically distinct 5 HT receptors have been identified. While this is a rapidly developing area, there is already some useful knowledge about the pharmacological correlates of many of these different receptor subtypes and how they may contribute to the therapeutic and adverse effects of antidepressant drugs.

**5-HT receptors, antidepressant action and adverse effects**

The antidepressant effect of SSRIs can be reversed by manipulations such as tryptophan depletion, which lower brain 5-HT synthesis.3 This indicates that sustained activation of post-synaptic 5-HT receptors is required for the therapeutic effect of SSRIs. However, the specific post-synaptic 5-HT receptors involved in the antidepressant action have not been identified definitively. Post-synaptic 5-HT1A receptors may play a role and selective 5-HT1A agonists such as buspirone and gepirone have antidepressant properties in clinical trials.4 However, the latter agents do not seem as useful in the treatment of depression as SSRIs because of restricted antidepressant efficacy and relatively poor tolerability. Overall if post-synaptic 5-HT1A receptors do play a role in the antidepressant action of SSRIs, it is likely to be in combination with other 5-HT receptor subtypes.

More progress has been made in understanding the 5-HT receptor subtypes involved in the adverse effects of SSRIs. For example it seems likely that stimulation of 5-HT3 receptors may be involved in the nausea that often accompanies the introduction of SSRI treatment.1 It is also possible that a number of the adverse effects of SSRIs could be mediated by activation of post-synaptic 5-HT2C receptors. For example, in both humans and animals, the 5-HT2C receptor agonist, m-chlorophenylpiperazine (mCPP), produces anxiety and sleep disruption.5 As well as reducing sleep continuity, mCPP lowers slow wave sleep, a stage of sleep important for memory consolidation.6 In contrast, drugs with 5-HT2C receptor blocking properties such as the antidepressant, mirtazapine and the atypical antipsychotic agent, olanzapine, increase slow wave sleep and sleep continuity.7,8 In animal models, acute administration of SSRIs increases anxiety and this effect can blocked by a selective 5-HT2C receptor antagonist.9

Taken together these data suggests that the early effects of SSRIs to produce anxiety, agitation and sleep disturbance are probably mediated through activation of 5-HT2C receptors. Another troublesome adverse effect of SSRIs in longer-term treatment is inhibition of ejaculation and orgasm. Animal studies suggest that this effect too may well be mediated in part by activation of 5-HT2C receptors.10,11

**Antidepressants with 5-HT2C receptor blocking properties**

The role of 5-HT2C receptors in the adverse effects of SSRIs suggests that combination of 5-HT2C receptor antagonists with SSRIs might be a useful therapeutic strategy from the

---

**Table 1: Clinical profile of some commonly used antidepressant medications**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Insomnia</th>
<th>Sedation</th>
<th>Nausea</th>
<th>Weight gain</th>
<th>Sexual dysfunction</th>
<th>Toxicity in Overdose</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRI</td>
<td>++</td>
<td>0</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>0</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>++</td>
<td>0</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>0</td>
</tr>
<tr>
<td>TCA</td>
<td>0</td>
<td>++</td>
<td>0</td>
<td>++</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>0</td>
<td>++</td>
<td>0</td>
<td>++</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

0 = not present, + = sometimes, ++ = common, TCA = Tricyclic Antidepressants and SSRI = Selective Serotonin Reuptake Inhibitors
Neupro® (rotigotine) is a thin, matrix-type square transdermal patch.

**Presentation:**
- **Neupro 2 mg/24 h transdermal patch:**
  - Releasing 2 mg rotigotine over 24 hours.
  - 10 cm² patch contains 4.5 mg rotigotine.
- **Neupro 4 mg/24 h transdermal patch:**
  - Releasing 4 mg rotigotine over 24 hours.
  - 20 cm² patch contains 9.0 mg rotigotine.
- **Neupro 6 mg/24 h transdermal patch:**
  - Releasing 6 mg rotigotine over 24 hours.
  - 30 cm² patch contains 13.5 mg rotigotine.
- **Neupro 8 mg/24 h transdermal patch:**
  - Releasing 8 mg rotigotine over 24 hours.
  - 40 cm² patch contains 18.0 mg rotigotine.

**Indications:**
To treat the signs and symptoms of idiopathic Parkinson’s disease, either with or without concomitant levodopa therapy.

**Dosage:**
Neupro is applied to the skin once a day. The patch remains on the skin for 24 hours and will then be replaced by a new one at a different application site.

- In monotherapy, treatment is initiated with a single daily dose of 2 mg/24 h. Dose increased by 2 mg/24 h each week up to a maximum of 8 mg/24 h.
- In combination with levodopa, treatment initiation is at 4 mg/24 h and increased weekly by 2 mg increments to a maximum dose of 16 mg/24 h.

**Contraindications:**
- Hypersensitivity to rotigotine or to any of the excipients. Neupro should be removed prior to Magnetic Resonance Imaging (MRI) or cardioversion to avoid burns.

**Warnings and Precautions:**
- External heat should not be applied to the patch. Dopamine agonists are known to cause hypotension, and monitoring of blood pressure is recommended. Where somnolence or sudden sleep onset occurs, or where there is persistent, spreading, or serious skin rash at the application site, consider dose reduction or termination of therapy.
- In case of generalized skin reaction associated with use of Neupro, discontinue treatment.
- Avoid exposure to direct sunlight until the skin is healed.
- If treatment is to be withdrawn, it should be gradually reduced to avoid symptoms of neuroleptic malignant syndrome.
- Compulsive behaviours and hallucinations have been reported in patients treated with dopamine agonists.

**Undesirable effects:**
- Very common side effects include nausea, vomiting, somnolence, dizziness, and application site reactions.
- Common side effects include anorexia, hallucinations, sleep attacks, insomnia, abnormal dreams, headache, dyskinesia, lethargy, orthostatic hypotension, hypertension, hiccups, cough, constipation, diarrhea, dry mouth, dyspepsia, hyperhidrosis, pruritus, asthenic conditions, and peripheral oedema.

**Basic NHS Cost:**
- Starter Pack: £110.34
- 2 mg Continuation Pack of 28 patches: £77.24
- 4 mg Continuation Pack of 28 patches: £88.28
- 6 mg Continuation Pack of 28 patches: £110.34
- 8 mg Continuation Pack of 28 patches: £142.79

**Legal Category:**
POM.
The tetracyclic antidepressants, mianserin and mirtazapine, do not inhibit the re-uptake of noradrenaline or 5-HT but have antagonist properties at 5-HT2C receptors. Both these drugs are relatively free from sexual dysfunction and, as noted above, promote sleep. However, they are complex molecules with several other pharmacological actions which makes analysis of the specific effects of 5-HT2C blockade difficult to assess. For example, both are strong histamine H1 receptor antagonists which may well contribute to their ability to improve sleep in depressed patients. H1 receptor antagonism may also cause the weight gain associated with mianserin and mirtazapine treatment. Mirtazapine and mianserin are also c2-adrenergic antagonists which would be expected to result in increased noradrenaline release from pre-synaptic noradrenergic terminals. This action, rather than 5HT2C receptor antagonism might therefore account for their antidepressant effects.

There is, however, evidence from basic studies that 5-HT2C receptor antagonism might have antidepressant potential. 5-HT pathways have inhibitory effects on dopamine and noradrenaline release through post-synaptic 5-HT2C receptors. In animal studies blockade of these receptors lead to increased release of both noradrenaline and dopamine, an action which might be expected to be associated with antidepressant effects. 

Agomelatine is a recently described molecule which combines melatonin agonist properties with 5-HT2C receptor blockade. Agomelatine is active in animal models of depression and also has proved efficacious in depressed patients in a number of placebo controlled trials. Interestingly the adverse effect profile of agomelatine does not include early anxiety and insomnia; in fact sleep continuity in depressed patients is improved and slow wave sleep increased. These early data suggest that 5-HT2C receptor antagonists and melanotergic agonist are worth exploring in depressed patients in a number of placebo controlled trials. Nevertheless, in a double blind, placebo controlled trial comparing agomelatine 8.8 micro g/day with placebo in 602 patients with major depression meeting DSM IV criteria, agomelatine failed to demonstrate superiority to placebo in the primary efficacy measure of the Maintenance of Remission to 18-24 weeks of treatment. Agomelatine does not significantly differ from placebo in the incidence of adverse events. A significant difference was observed in the change from baseline to endpoint in the HDRS total score which was a statistically significant improvement in the agomelatine group. However, the clinical significance of this finding is questionable due to the wide standard deviation. Nevertheless, the results of this study indicate that agomelatine is not a superior antidepressant to placebo in the treatment of major depression. Further studies are awaited to confirm or refute these results.

Agomelatine is currently being developed for the treatment of other mood disorders, such as bipolar disorder, but the data available thus far do not appear promising. As with most new antidepressant treatments there is a need for more controlled studies and longer follow up periods to confirm the clinical significance of the initial findings. Nevertheless, agomelatine is the first 5HT2C receptor antagonist to reach late stage clinical development and has the potential to become an important addition to the antidepressant armamentarium. Further large scale clinical trials will be awaited with interest to confirm the initial promising results.

Agomelatine is a novel compound which has been shown to have antidepressant efficacy and to improve sleep. It is a 5-HT2C receptor antagonist and a melatonergic agonist. Agomelatine is effective in the treatment of major depression and is under development for other mood disorders, such as bipolar disorder. The potential for agomelatine to improve sleep in depression is of particular interest as sleep disturbance is a common symptom in depression. Agomelatine has been shown to be effective in improving sleep in depressed patients in placebo controlled trials. The side effect profile of agomelatine is generally acceptable with the most common adverse events being dizziness, nausea and dry mouth. Agomelatine is well tolerated by patients with a good level of compliance. The efficacy and safety of agomelatine have been demonstrated in several large scale clinical trials. Agomelatine is a promising new treatment for depression and further studies are awaited to confirm its clinical effectiveness.
Titration made easy

Easy titration for Rebif initiation

Until there’s a cure.
Mitochondrial Disease: Old and New

The mitochondrion is an intracellular organelle with the primary function of generating ATP, the energy currency of the cell, by oxidative phosphorylation. It also hosts beta oxidation, the Krebs cycle and other pathways. Mitochondrial dysfunction is particularly prominent in the energy dependent tissues brain and muscle. In some diseases, mitochondrial dysfunction is part of the pathophysiology (e.g. Parkinson’s disease); in others a mitochondrial enzyme deficiency is the primary cause of the disease.

The complexity of mitochondrial disease is increased by the presence of copies of mitochondrial DNA (mtDNA) within the organelle. Human mtDNA is a 16.6 kb circular double stranded DNA molecule. It contains 13 genes for protein subunits of the mitochondrial respiratory chain. A further 2 genes encode ribosomal RNA, and there is a complete set of 22 tRNAs. The mtDNA encoded proteins are subunits of respiratory chain complexes I, III, IV and V, while the subunits of complex II are entirely nuclearly encoded. Because there are multiple copies of mtDNA within each mitochondrion, cell and tissue, the concept of heteroplasmy arises, in which there is a mix of different mtDNAs. In mitochondrial disease heteroplasmy is common, with normal mtDNA coexisting with abnormal mtDNA.

This article is necessarily selective and describes:
- a scheme of investigation for classical mitochondrial respiratory chain disease (often easy to diagnose)
- a discussion of more recently described mitochondrial disorders and those more difficult to diagnose

Classical mitochondrial encephalomyopathies

It is often stated that mitochondrial disease is clinically and genetically heterogeneous, and is protein in its manifestations. It would therefore be expected that the diagnosis of mitochondrial disease is often overlooked and misdiagnosed. Whereas this may happen, most experienced neurologists meeting a patient with mitochondrial disease will consider the diagnosis in timely fashion, although genetic classification may take somewhat longer. The reason for the diagnostic success lies in the fact that although presentations are highly variable, mitochondrial disease rises to the top of the differential diagnosis. This should lead to a comprehensive review to look for further features in the patient and their family. When the diagnosis is suspected, it may usually be confirmed by the appropriate use of genetic analysis of blood or muscle, and histochemical examination of muscle. Table 2 details the usual scheme of investigation. A genetic diagnosis from blood may be possible, but if not muscle biopsy usually shows focal histochemical abnormalities, with proliferation of mitochondria seen as ragged red fibres on the modified Gomori trichrome reaction. Research techniques such as in situ hybridisation show these abnormal fibres to be populated by mutant DNA (Figure 1). Such fibres react heavily with succinic dehydrogenase, which is not mtDNA encoded, but are usually deficient in cytochrome oxidase (COX), which is.

Mitochondrial encephalopathies

Mitochondrial encephalopathies can present at any age. Presentations in childhood have a higher incidence of multisystem disease, with short stature, bone marrow, cardiac and renal involvement often seen. Mitochondrial encephalopathies sometimes conform to the acronyms MERRF (myoclonic epilepsy with ragged red fibres) or MELAS (mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), but more often do not. The value of the acronyms is to provide a mnemonic for some of the more common manifestations of mitochondrial encephalopathy, and the clinical features have an approximate correlation with the two commonest mtDNA point mutations (mtDNA 8344 tRNAlys and 3243 tRNALeu(UUR) respectively). However, dementia, ataxia and deafness are also common CNS features and even within families the clinical features vary qualitatively and

![Figure 1: A muscle biopsy of a patient with a heteroplasmic mtDNA deletion. In situ hybridization using a probe detecting deleted mtDNA species showing them to be concentrated within ragged red fibres (RRF).](image)

### Table 1: Common features of classical mitochondrial disease

<table>
<thead>
<tr>
<th>Eyes</th>
<th>Ptosis and ophthalmoplegia</th>
<th>Retinopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatic</td>
<td>Diabetes</td>
<td>Deafness</td>
</tr>
<tr>
<td>Short stature</td>
<td>Cardiac, renal involvement</td>
<td>Sideroblastic anaemia</td>
</tr>
<tr>
<td>CNS</td>
<td>Dementia</td>
<td>Ataxia</td>
</tr>
<tr>
<td></td>
<td>Myoclonus</td>
<td>Seizures</td>
</tr>
<tr>
<td></td>
<td>Strokelike episodes</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: Investigation of mtDNA disorders

<table>
<thead>
<tr>
<th>Presentation</th>
<th>First investigation</th>
<th>Further investigation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEO, KSS or myopathy</td>
<td>Muscle biopsy</td>
<td>Muscle mtDNA analysis including deletions</td>
</tr>
<tr>
<td>Encephalopathies</td>
<td>mtDNA analysis (blood) for common point mutations</td>
<td>Muscle biopsy</td>
</tr>
<tr>
<td>Leber’s hereditary optic neuropathy</td>
<td>mtDNA analysis (blood)</td>
<td></td>
</tr>
<tr>
<td>NARP/MILS</td>
<td>mtDNA analysis (blood)</td>
<td></td>
</tr>
</tbody>
</table>

KSS = Kearns Sayre syndrome, NARP = Neurogenic weakness, ataxia, retinitis pigmentosa, MILS = maternally inherited Leigh’s syndrome.
Azilect® 1mg tablets  Prescribing information

(Please refer to the Summary of Product Characteristics (SmPC) before prescribing)

Presentation: Tablets containing 1mg rasagiline (as the mesilate).

Indication: Treatment of idiopathic Parkinson’s disease as monotherapy or as adjunct to levodopa in patients with end of dose fluctuations. Dosage and administration: Oral; 1mg once daily taken with or without food. Elderly: No change in dosage required. Children and adolescents (<18 years): Not recommended. Patients with renal impairment: No change in dosage required. Patients with hepatic impairment: Predominant hepatic metabolism. Do not use in patients with severe impairment. Avoid use in patients with moderate impairment. Use with caution in patients with mild impairment and stop if progresses to moderate.

Contraindications: Hypersensitivity to the active substance or to any of the excipients. Do not use in patients with severe hepatic insufficiency. Co-administration of other monoamine oxidase (MAO) inhibitors is contraindicated due to risk of hypertensive crises. Concomitant pethidine treatment is contraindicated. Allow at least 14 days off rasagiline before using other MAO inhibitors or pethidine.

Special warnings and precautions: Administer antidepressants with caution as serious adverse reactions have been reported with concomitant use of selective serotonin reuptake inhibitors, tricyclic and tetracyclic antidepressants, MAO inhibitors and a selective MAO-B inhibitor. Avoid concomitant use with fluoxetine or fluvoxamine. Leave at least five weeks between discontinuation of fluoxetine and initiation of treatment with rasagiline or fluvoxamine. Administer patient CYP1A2 inhibitors with caution. Co-administration with dextromethorphan or sympathomimetics not recommended. Avoid use in patients with moderate hepatic impairment. Use caution in patients with mild hepatic impairment. Use with caution in pregnancy or lactation. There is an increased risk of skin cancer in Parkinson’s disease, not associated with any particular drug. Suspicious skin lesions require specialist evaluation. Undesirable effects in clinical trials: Monotherapy: >1%: headache, flu syndrome, malaise, neck pain, dizziness, arthralgia, depression, conjunctivitis, fever, angina pectoris, anorexia, leukopenia, arthralgia, vertigo, rhinitis, contact dermatitis, vesiculobullous rash, skin carcinoma, hallucinations, urinary urgency. <1%: cerebrovascular accident, myocardial infarct. Adjunct therapy: >1%: abdominal pain, accidental injury, postural hypotension, constipation, vomiting, weight loss, dyskinesia, neck pain, anorexia, dry mouth, arthralgia, tachycardia, dyspnea, abnormal dreams, asthenia, rash, hallucinations. <1%: anorexia, dry mouth, arthralgia, tachycardia, dyspnea, abnormal dreams, asthenia, rash, hallucinations.

Basic NHS Price: £70.72

Marketing Authorisation Number: EU/1/04/304/003

Marketing Authorisation Holder: Teva Pharma GmbH, Kandelstr 10, D-79199 Kirchzarten Germany

Date last revised: April 2007

Further information available from: Lundbeck Limited, Lundbeck House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LG

Information about adverse event reporting can be found at www.yellowcard.gov.uk

Adverse events should also be reported to Teva Pharmaceuticals Ltd on telephone number: 01296 719 768.


PEO is often combined with other clinical features, and can range from late onset pure PEO to more severe variants such as the Kearns-Sayre syndrome. Although some degree of proximal limb weakness is common, a pure limb girdle syndrome without clues such as PEO, deafness, or somatic features is relatively rare. Petty et al pointed out that if the patient has no CNS manifestations of disease within 5 years of onset, then these are unlikely and the diagnosis correspondingly much better than the mitochondrial encephalomyopathies. Muscle involvement rarely causes severe weakness, and loss of mobility secondary to muscle weakness alone is rare.

PEO can be sporadic with very low recurrence risk (single large heteroplasmic mtDNA deletion), or with maternal (heteroplasmic mtDNA mutation), or autosomal inheritance (see below). Thus genetic investigation is important to define recurrence risks.

The commonest abnormality causing mitochondrial PEO is a single large mtDNA deletion. This is present in much large proportion in muscle, and a muscle biopsy remains the definitive investigation for histochemical studies and genetic analysis.

**Therapeutics in mitochondrial disease**

A Cochrane review concluded that there was no clear evidence supporting any therapeutic intervention in mitochondrial disorders.1 Exercise training appears to help patients and is probably safe.2 Some patients report subjective improvement in muscle symptoms on Coenzyme Q10 or creatine supplements. The author has observed abrupt improvement in treating stroke-like episodes acutely with dexamethasone, but this is unlikely to be trialled.

Supportive treatment for the many other manifestations of these disorders remains valuable.

**New and more difficult mitochondrial disease**

The characteristics of classical mitochondrial disease establish useful guidelines to the clinician and scientist. Maternal inheritance, multi-system disease, focal histochemical abnormalities on muscle biopsy, and heteroplasmic mtDNA are all typical of these diseases. Clinical and molecular diagnosis becomes more challenging when these features are not present. Examples of such patients not conforming to the classical model are increasingly described, and are summarised here.

**Absence of typical histochemistry**

Mitochondrial encephalomyopathies are historically defined by the presence of ragged red fibres (RRF) in muscle, an indicator of pathological focal mitochondrial proliferation. Diseases without this hallmark or without any histochemical markers of mitochondrial dysfunction are more difficult to identify. The characteristic phenotype of Leber’s hereditary optic neuropathy is not associated with mitochondrial histochemical defects, and similarly RRF are not found in the biopsies of NARP patients (which usually show evidence of denervation). More difficult are the few patients with classical mitochondrial phenotypes such as MELAS and others. Such phenotypes are usually associated with mtDNA tRNA mutations, but less commonly can be associated with mutations in protein coding genes. Mutations in protein coding genes such as mtDNA ND5, often do not cause histochemical abnormalities on muscle biopsy.3 When abnormalities are found, they are subtle, with increased staining of the succinic dehydrogenase reaction in cytochrome oxidase positive fibres.

**Absence of family history or multisystem disease**

Some patients with muscle symptoms such as fatigue and exercise intolerance (sometimes with episodic myoglobinuria) also have mutations in mtDNA protein coding genes. Such patients are difficult to identify because there may be no maternal family history and no manifestations outside muscle.4 This group of patients do have abnormalities on muscle biopsy which often acts as a spur to more directed mtDNA analysis. Unless the mtDNA mutation involves COX genes, the RRF are COX positive, which is an additional clue.

**Absence of mtDNA heteroplasmy**

LHON is more often due to mutations in the homoplasmic rather than heteroplasmic state. Homoplasmic mtDNA mutations causing other mitochondrial disease are rare, but has now been described in several families, although the pathogenicity of the mutation is always harder to prove.5

**No mtDNA defect**

mtDNA encodes only 13 of the 90 (approximately) proteins of the respiratory chain, leaving much scope for respiratory chain defects secondary to nuclear gene defects, as well as many other mitochondrial proteins. These disorders may have similar clinical and biochemical features to mtDNA disease and may be difficult to define in molecular terms. Many of these mutations cause severe or fatal early onset disorders, such as SURF1 mutations which are the commonest cause of typical Leigh’s disease. These numerous disorders are beyond the scope of this review.

**Intergenomic disease**

Whereas the initial thrust of research and understanding of mitochondrial disease was largely confined to the primary disorders of mitochondrial DNA, a more recent research priority has been the elucidation of disorders arising from defects in the interaction of the two genomes. These disorders are caused by nuclear gene defects involved in mtDNA maintenance; consequently Mendelian inheritance is observed. These defects give rise to direct or

---

**Table 3: mtDNA disorders without RRF or histochemical deficit.**

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genetic abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td>LHON</td>
<td>mtDNA mutations account for ~95% of disease</td>
</tr>
<tr>
<td>NARP/MILS</td>
<td>mtDNA ATPase mutations</td>
</tr>
<tr>
<td>Some patients with MELAS and other encephalopathies</td>
<td>mtDNA mutations in ND5 and other protein coding genes</td>
</tr>
</tbody>
</table>

LHON = Leber’s hereditary optic neuropathy.
indirect injury to mtDNA through different pathways, either quantitative or qualitative. However, as might be predicted, the biochemical, pathological and clinical consequences are often suggestive of mitochondrial disease. MtDNA is continuously recycled. Replication is performed by a number of nuclear encoded proteins. MtDNA polymerase (POLG) is the only DNA polymerase present in mammalian mitochondria. It is a heterodimer with a catalytic subunit (coded by POLG) and two identical accessory subunits (coded by POLG2). The accessory subunit is a DNA binding factor required to increase the affinity of the heterotrimer for template DNA. POLG together with other nuclearly encoded proteins is central to the synthesis of mtDNA. Other proteins involved in mtDNA maintenance and associated with human disease are tabulated (Table 4).

**POLG mutations**

**Autosomal dominant disease**

POLG came to attention when pathogenic mutations were discovered to cause autosomal dominant PEO (adPEO). It is now apparent that POLG defects account for about half of adPEO. In such patients, multiple defects are found in mtDNA with muscle biopsy findings indicating a mitochondrial myopathy. PEO is associated with a variable number of other clinical manifestations. Clinically patients with adPEO may have a similar phenotype to patients with PEO due to a single deletion or a mtDNA mutation. Some additional features such as deafness and neuropathy are common accompaniments of mitochondrial disease, but some families show an excess of cataracts, parkinsonism and psychiatric disorders. POLG or other nuclear mutations may be suspected if autosomal inheritance is present, or if mtDNA analysis raises the possibility of multiple deletions or depletion.

**Autosomal recessive disease**

Compound heterozygotes for POLG mutations may also show ophthalmaparesis. However, neuropathy and ataxia are common additional features, giving rise to the acronym SANDO (sensory ataxic neuropathy with dysarthria and ophthalmaparesis). Recessive POLG mutations may also cause adult onset ataxia without ophthalmoplegia (mitochondrial recessive ataxia syndrome or MIRAS).

POLG mutations are not a rare cause of mitochondrial disease and the phenotype is expanding, ranging from fetal childhood hepatoopathy (Alpers syndrome) to milder clinical syndromes in later life.6 Whereas the diagnosis is often suggested by the muscle biopsy, biochemical and mtDNA findings, clinicians may suspect the diagnosis when autosomal inheritance is evident or clinical features match those tabulated (Table 5).

The phenotype of POLG gene variants is still expanding. There are several reports of deterioration on initiation of valproate, and it is prudent to avoid this medication if POLG associated disease is suspected.

**Other nuclear mutations causing mtDNA deletions and depletion**

This is currently an active area of research, with an increasing number of genes implicated (Table 4). The latest gene investigated is RRM2B, which accounts for the depletion syndrome in further families.7 More causative genes are likely to be identified as some families with deletions/depletion do not have a known causative gene.

**Thymidine phosphorylase mutations**

Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is an autosomal recessive disorder caused by mutations in the thymidine phosphorylase gene. The phenotype is relatively stereotyped with onset often in late childhood with PEO, and cachexia secondary to gastrointestinal dysmotility. A demyelinating neuropathy may be initially asymptomatic or may be the presenting feature, mimicking CIDP.8 A striking leukoencephalopathy seen on magnetic resonance imaging of the brain remains asymptomatic.9

Disability results from the neuropathy as well as myopathy, but the gastrointestinal manifestations cause cachexia and life threatening complications. As a consequence of loss of function of thymidine phosphorylase, blood levels of thymidine and deoxyuridine are raised. Alterations of nucleoside metabolism cause preferential impairment of mtDNA replication, leading to both depletion and deletions on mtDNA.

Elucidation of the biochemical disturbance has led to the possibility of therapeutic intervention, by restoring thymidine phosphorylase function. Allogeneic stem cell transplantation is one approach, already shown to be capable of improving the plasma levels of nucleosides, but it is not clear whether this will have a beneficial effect on cellular function. This approach has not yet been shown to produce significant clinical improvement.

### Table 4: Gene, Protein, MIDNA defect, Clinical syndrome

<table>
<thead>
<tr>
<th>Gene</th>
<th>Protein</th>
<th>MIDNA defect</th>
<th>Clinical syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>POLG1</td>
<td>polymerase γ-alpha subunit catalytic subunit p140</td>
<td>Multiple deletions and depletion</td>
<td>See text ad/arPEO, ad/ar multisystemic syndromes</td>
</tr>
<tr>
<td>POLG2</td>
<td>polymerase γ-alpha subunit accessory subunit p55</td>
<td>Multiple deletions and depletion</td>
<td>Alpers syndrome</td>
</tr>
<tr>
<td>C10orf2</td>
<td>mitochondrial helicase PEO1 (Twinkle)</td>
<td>Multiple deletions</td>
<td>adPEO, atIOSCA, ar hepatocerebral syndrome</td>
</tr>
<tr>
<td>ANT1</td>
<td>adenine nucleotide translocator 1</td>
<td>Multiple deletions</td>
<td>ad/arPEO</td>
</tr>
<tr>
<td>TP</td>
<td>thymidine phosphorylase</td>
<td>multiple deletions and depletion</td>
<td>MNGIE</td>
</tr>
<tr>
<td>dCK</td>
<td>deoxycytidine kinase</td>
<td>Depletion</td>
<td>Hepato-cerebral syndrome</td>
</tr>
<tr>
<td>SUCCLA2</td>
<td>beta subunit of the ADP-forming succinyl-CoA synthetase ligase</td>
<td>Depletion</td>
<td>Encephalomyopathy and anemia</td>
</tr>
<tr>
<td>MPV17</td>
<td>MPV17 inner mitochondrial membrane protein</td>
<td>Depletion</td>
<td>Hepato-cerebral syndrome</td>
</tr>
<tr>
<td>TK2</td>
<td>thymidine kinase 2</td>
<td>Depletion</td>
<td>Myopathic syndrome</td>
</tr>
<tr>
<td>RRM2B</td>
<td>P53 controlled ribonucleotide reductase</td>
<td>Depletion</td>
<td>Fatal infantile multisystem disease</td>
</tr>
</tbody>
</table>

ad/ar = autosomal dominant/autosomal recessive, IOSCA = infantile onset spinocerebellar ataxia.

### Table 5: Clinical features suggestive of POLG mutations

- Onset at any age but neurological features commonly in teens
- Epilepsy is the most frequent presenting symptom (often with headache and sometimes resulting in status epilepticus)
- Axonal neuropathy is present in most patients
- Myopathy, ataxia, PEO are also common
- PEO is not invariably present and usually appears after age 20
- Alper’s disease is caused by POLG mutations, and valproate may precipitate hepatic failure in neurological patients carrying POLG mutations
Co-enzyme Q10 deficiency

Coenzyme Q10 is a respiratory chain cofactor. Deficiency states would be predicted to cause respiratory chain dysfunction. Co-enzyme Q10 deficiency has been reported in association with diverse presentations from early onset encephalomyopathy often with fatal renal involvement, to later onset and milder myopathic presentations. This heterogeneous condition is now being elucidated. Nine enzymes are involved in Co-enzyme Q10 biosynthesis. To date pathogenic mutations have been described in three of these enzymes, PDSS1, PDSS2, and COQ2.12 It has been shown that what has been described as the myopathic form of co-enzyme Q10 deficiency is a presentation of late onset glutaric aciduria. Recessive mutations in the electron transferring flavoprotein dehydrogenase gene (ETFDH) have been identified.13

The importance of these disorders is the potential response to Co-enzyme Q10 supplementation, including the secondary deficiency seen in glutaric aciduria. High doses may be needed, and the case of the myopathic presentations additional riboflavin may be required. Whereas the myopathic presentation may be suggested by lipid accumulation and mitochondrial changes on muscle biopsy, the primary deficiencies showed no such clues, and Co-enzyme Q10 assay on muscle or fibroblasts may be advisable in suggestive presentations to detect therapeutic possibilities.

Conclusion

Classical mitochondrial disorders affecting the nervous system are often diagnosed promptly by neurologists, but this article has shown that mitochondrial disease may not always be associated with expected patterns of inheritance, muscle histochemistry, and molecular genetic abnormalities. Consequently, mitochondrial disease must be considered beyond the classical mitochondrial phenotypes. Recent therapeutic attempts with respect to MNGIE and coenzyme Q10 deficiency are still being evaluated and may herald the start of a new era of therapeutic options in mitochondrial disease.

References

“Neurological literature”: Headache (Part 4)

“Existence is just an ache in the head” – Margiad Evans, diary entry for 23rd November 1949

T

hat headache has been a feature of the human condition since prehistory may be inferred by the finding of skulls with holes cut in them. Such trepanations date from as far back as the Neolithic era, and have been found in Europe, Asia, the Americas, and north Africa.1 Although their purpose will forever be obscure to us, the possibility that they were undertaken to relieve headache, perhaps through a perception that such surgery would release malign spirits from inside the head, seems at least plausible. Recourse to such extreme, life-threatening, measures may suggest the presence of severe symptoms.

That no record of headache is to be found, as far as I am aware, in the doings of the numinous, extracorporeal, God of the Jews and Christians is perhaps no surprise. Nor that the domestic soap opera of the Olympian gods of ancient Greece, amounting at times almost to farce (e.g. the Homeric epics Iliad and Odyssey), should give an example of something so quotidian as headache, specifically in one of the myths of the birth of Athene, the goddess of wisdom.2,3 Zeus, ruler of the gods, lusted after Metis the Titaness; she has been identified with the planet Mercury, itself associated with wisdom. Having gained his wicked way with Metis, Zeus was warned by a prophecy that she would bear a son strong enough to depose him, in the same way that Zeus himself had deposed his father Cronos with the assistance of Metis.

To avoid this eventuality, Zeus swallowed Metis. However, this was not the end of the matter: “In due course, his fructification is consummated, his offspring is a charm: chanting the charm at the same time as using herbs or the sufferer from migraine will … easily recognize Charms, with their appeal to the supernatural, may be one of the most ancient forms of headache treatment. John Kirk, medical officer on David Livingstone’s expedition to the Zambesi between 1858 and 1863,4 noted amongst the indigenous people the use of charms, such as fruit, for treatment of, amongst other things, headache.

Unlike Plato’s transcendentalism, we may rely on Aristotle for sound empirical observation. In the Historia animalia, he reports (Book 5, chapter 31) that those with lousy heads are “less than ordinarily troubled with headache”, but sadly proposes no mechanism for this beneficial effect of the humble head louse. Later, he reports (Book 7, chapter 4) that after conception women experience a sensation of headache in front of the eyes and suffer also from heaviness throughout the body and darkness before the eyes, these symptoms occurring as early as the tenth day. A humoral mechanism is adduced (“according as the patient be more or less bushered with superfulous humours”).Saints may perhaps have taken the place of charms in Christian iconography. As mentioned in a previous article,5 St Stephen, the first Christian martyr, was invoked against headaches because of the manner of his death by stoning. He was not alone: in Brittany, legend has it that there are 7777 local saints, enough to intercede for every eventualty, including Saint Livertin for headaches. In the Koran (Chapter LVI), when the “inevitable” happens, the “foremost” shall enjoy a cup of flowing wine and “no headache shall they feel therefrom, nor shall their wits be dimmed”.

The abbess Hildegard of Bingen (1098-1179) was a woman of extraordinary intellectual ability, whose works include volumes dealing with illness and medical treatment, the Causae et curae and Physica.6 Throughout her long life she had visions, which she believed to be divinely inspired and which she used to inform and illustrate her theological works (e.g. Scivias, Liber divinorum operum). Writing on “The visions of Hildegard of Bingen”, Charles Singer suggested that “the medical reader or the sufferer from migraine will … easily recognize the symptoms of ‘scintillating scotoma’”, a theme later taken up by Oliver Sacks who found the visions to be “indisputably migraineous in nature”.7 Indeed, perhaps as a consequence of this, she has attracted the label of “The most distinguished migraine sufferer” (see www.fordham.edu/halsall/med/hildegarde.html).

Charms, with their appeal to the supernatural, may be one of the most ancient forms of headache treatment. John Kirk, medical officer on David Livingstone’s expedition to the Zambesi between 1858 and 1863,4 noted amongst the indigenous people the use of charms, such as fruit, for treatment of, amongst other things, headache.

Unlike Plato’s transcendentalism, we may rely on Aristotle for sound empirical observation. In the Historia animalia, he reports (Book 5, chapter 31) that those with lousy heads are “less than ordinarily troubled with headache”, but sadly proposes no mechanism for this beneficial effect of the humble head louse. Later, he reports (Book 7, chapter 4) that after conception women experience a sensation of headache in front of the eyes and suffer also from heaviness throughout the body and darkness before the eyes, these symptoms occurring as early as the tenth day. A humoral mechanism is adduced (“according as the patient be more or less bushered with superfulous humours”).Saints may perhaps have taken the place of charms in Christian iconography. As mentioned in a previous article,5 St Stephen, the first Christian martyr, was invoked against headaches because of the manner of his death by stoning. He was not alone: in Brittany, legend has it that there are 7777 local saints, enough to intercede for every eventualty, including Saint Livertin for headaches. In the Koran (Chapter LVI), when the “inevitable” happens, the “foremost” shall enjoy a cup of flowing wine and “no headache shall they feel therefrom, nor shall their wits be dimmed”.

The abbess Hildegard of Bingen (1098-1179) was a woman of extraordinary intellectual ability, whose works include volumes dealing with illness and medical treatment, the Causae et curae and Physica.6 Throughout her long life she had visions, which she believed to be divinely inspired and which she used to inform and illustrate her theological works (e.g. Scivias, Liber divinorum operum). Writing on “The visions of Hildegard of Bingen”, Charles Singer suggested that “the medical reader or the sufferer from migraine will … easily recognize the symptoms of ‘scintillating scotoma’”, a theme later taken up by Oliver Sacks who found the visions to be “indisputably migraineous in nature”.7 Indeed, perhaps as a consequence of this, she has attracted the label of “The most distinguished migraine sufferer” (see www.fordham.edu/halsall/med/hildegarde.html).
Neuropathology in Context

Introduction
Neuropathology is the naked eye (macroscopic) and microscopic study of the nervous system and its diseases. Its main purpose is to determine the causes and effects of disease in the nervous system; in this way neuropathology plays a major role in the multidisciplinary team of clinicians caring for and investigating patients with neurological disease.

But how did it all start? In this article, I trace the origins of neuropathology, its development through the centuries and its evolution into the 21st Century.

Neuroscience in ancient times
Records of interest in the nervous system date back to Ancient Greece but it was probably Herophilus of Chalcedon (335-280 BC) who first proposed that the brain is the centre of intelligence rather than just a cooling system to chill the ardours of the heart, as taught by Aristotle. Subsequently, Galen, in the second century AD, expanded the then popular pneumatic theory of the brain. This theory proposed that the vital spirit entered through the eyes and was purified in the ventricular system of the brain to form the animal spirit which in turn was distributed around the body by the arteries and nerves. Waste products from this refining process were dispersed into the nose or the sinuses. According to the pneumatic theory, the major functions of imagination, cogitation (thinking) and memory resided in the different parts of the cerebral ventricular system.

These views were still prevalent in the 16th Century in Europe at the dawn of Modern Neuroscience when Vesalius published detailed anatomical drawings of the brain (Figure 1) in his book De humani corporis fabrica in 1543. Vesalius also described neuropathological conditions such as hydrocephalus in children with enlargement of the head and attenuation of the cerebral brain tissue around expanded ventricles that contained excessive amounts of fluid quantified in “Augsburg wine measures”.

Early development of neuropathology
With the increasing availability of microscopes during the 19th century, peripheral nerves were the first parts of the nervous system to be studied in detail. Robert Remak described non-myelinated nerve fibres and ganglion cells in 1838. He recounted how he prayed for sunshine in the Berlin winter as microscopes relied upon natural light, so on cloudy days he saw nothing. Remak’s contemporary in Berlin, Theodore Schwann, is credited with the description of Schwann cells in 1839, although he described them as a syncytium rather than separate cells surrounding a continuous axon. Augustus Waller, in London, followed with his description of axonal (Wallerian) degeneration in 1850. Detailed descriptions of the anatomy and pathology of separated “teased” nerve fibres were published in 1878 by Ranvier in Paris. One of his suggestions for the function of étranglements annulaires (nodes of Ranvier) was that they prevented the semi-liquid myelin from flowing down the nerve while standing. Many neurological syndromes were described in France in the last decades of the 19th century, perhaps most famously by Charcot who also described the pathology of sclerosis en plaque (multiple sclerosis).

Development of histological techniques to separate the mature and immature nervous system. However, the number of different names for brain tumours expanded so much that in 1949 Kernohan simplified the classification by introducing a Grading System for brain tumours based on their predicted behaviour with Grade 1 at the benign end of the spectrum and Grade 4 at the more malignant end. A similar but modified Grading System has been used in all the World Health Organisation Classifications of Tumours of the Nervous system published between 1973 and 2007.

Descriptive neuropathology flourished during the first half of the 20th century in Europe and the USA and resulted in the first major English language text book of neuropathology, published by Greenfield and colleagues in London in 1958. At that time many diseases carried long
Neuropathology in the second half of the 20th century

This era witnessed an explosion of new technology for investigation and research into nervous system pathology. Electron microscopy was introduced in the 1950s and immunocytochemistry in the 1970s; these two techniques have probably had the greatest direct impact on neuropathology. Electron microscopy revealed the fine detail of brain cytology, showed the arrangement of neuronal and glial structures in the previously featureless neuropil and defined the tight junctions between endothelial cells associated with the blood-brain barrier (Figures 3 & 4). Scanning electron microscopy visualized the three-dimensional relationships of many structures in the nervous system and the associated meninges (Figure 5). The introduction of immunocytochemistry allowed the chemical definition of many of the structures discovered by electron microscopy and the more reliable identification of the different types of cell in the normal and diseased nervous system (Figures 6 & 7).

With the introduction of computerised tomography (CT) and magnetic resonance imaging (MRI) neuropathology became visible in the living patient. The pathological identities of the lesions seen in CT and MRI scans were determined by correlating the appearances in scans with the histological analysis of biopsies and post-mortem brains. Many thought that the need for neuropathology as a clinical diagnostic service would decline and perhaps disappear altogether and be supplanted by CT and MRI. This did not happen as the gold standard for diagnosis still largely rests upon histological diagnosis, especially for tumours.

Neuropathology in the 21st Century

The 21st century has seen an increasing role for neuropathology in a wide range of disciplines within neuroscience, ranging from the diagnosis of lesions in individual patients and monitoring the effects of therapy to research into the causes and mechanisms of disease.

Why does it take more than five years or more of postgraduate study to train a consultant neuropathologist? The main reason is the complexity of the nervous system and the wide spectrum of its pathology, ranging from focal disease in the brain and spinal cord (e.g. tumours, infarcts, abscesses and multiple sclerosis plaques) to the more diffuse diseases of the brain such as the many different types of dementia, movement disorders and hereditary diseases. Interpretation of neuropathological specimens requires an in-depth knowledge of the structure and function of the nervous system and a very good working knowledge of clinical diagnostic neurology, neurosurgery and psychiatry.

Much of the work load of a consultant neuropathologist in one of the Regional Neurological and Neurosurgical Centres in Britain is the diagnosis of lesions in the brain, spinal cord, muscle or peripheral nerve in biopsy specimens removed at surgery. Intra-operative diagnosis of tumours, by the use of smear preparations and cryostat sections, is often required. This is followed by a final diagnosis based on paraffin sections stained by histological and immunohistochemical techniques and the correlation of histological findings with the clinical and radiological data. The neuropathological diagnosis usually forms the basis for discussion at the Multidisciplinary Team (MDT) Meetings involving a wide variety of clinicians and scientists (Figure 8). Communication, audit, education and quality control at MDT meetings form a basis for Clinical Governance and the maintenance of high quality care for patients.

The neuropathology of neurological, psychiatric and forensic disorders is usually investigated in post-mortem brains with close correlation between pathology and clinical findings. This process is particularly important for the investigation of dementias, movement disorders and infections. Working with coroners and the police on the examination of medico-legal cases may entail appearances in court, often to argue a case in the face of differing opinions.

Neuropathology in the future

What does the future offer? As long as there are unresolved problems in the causes, diagnosis and treatment of neurological disease, there will be a need for information on the structural aspects and cell pathology of the nervous system. Neuropathology will remain a very importantlynch-pin in clinical management and research. Knowledge of the pathology of the human nervous system will always be required to guide research efforts in experimental neuroscience to the most relevant areas of investigation.

Borders between disciplines in medicine are often blurred and this applies to neuropathology and closely related disciplines in clinical and basic neuroscience. Many neuropathology laboratories combine structural, molecular biological and genetic analyses of tissue samples to gain a complete picture of the disease process affecting the patient. This trend is likely to grow and produce an increasingly integrated approach based on the cell biology of diseases of the nervous system.
Electroencephalography (EEG) and Functional Magnetic Resonance Imaging (fMRI) are two important techniques for the study of the human brain, healthy or diseased. For example, EEG is of primary importance in the clinical evaluation of patients with epilepsy, by allowing the visualisation of very brief (order of ms) electrophysiological abnormalities during seizures and between seizures, such as interictal spikes (focal epileptic spikes). EEG can therefore provide specific markers of epilepsy containing some localising information in relation to an underlying brain abnormality responsible for the epilepsy. EEG is also capable of recording patterns linked to specific external (visual, sensorial, etc) stimuli, in the form of evoked responses. Salient features of the scalp EEG, such as spikes or rhythms, reflect increased synchronisation of cortical activity at various spatial scales, ranging from sub-lobar to the entire brain. Simulations and experimental data have shown that such EEG features must involve a patch of cortex with an area of at least 10 cm\(^2\). Crucially, scalp EEG is most sensitive to superficial cortical activity with limited or no sensitivity to events taking place deeper in the brain such as on the medial aspect of the temporal lobe, which are only detectable via propagation to more superficial cortex.

Some localising information on the generators of EEG features can be derived qualitatively from visual inspection of the recordings by experienced observers, mainly based on consideration of the feature's amplitude in relation to the various channels particularly for discharges such as focal epileptic spikes. In patients with drug-resistant epilepsy who may benefit from surgery EEG recordings combined with careful examination of the clinical manifestations observed during seizures (such as recorded on video-EEG telemetry) are capable of providing very useful information, but at the lobar level. Focal spikes being much more common than seizures, a great effort has been made to use these for localisation purposes. Although in general spikes may originate from outside the epileptic focus itself (their generator is called the irritative zone), in many cases there is considerable overlap. In theory, spike generator localisation can be improved on using computational EEG source reconstruction methods based on assumptions on the form of the EEG generators. The simplest and commonest assumption is that EEG generators can be represented as electrical dipoles, consisting of combined positive and negative sources. Although widely used in research this type of localisation has had limited impact on clinical practice in large part due to uncertainties in the modelling assumptions.

Functional MRI

Therefore, EEG-based localisation remains limited in accuracy and clinical utility. On the other hand functional MRI, in the form of activation maps derived from series of scans, is a powerful tool for visualising changes linked to epochs of specific brain activity contrasted to a control state. Two great advantages of fMRI are its more or less equal sensitivity irrespective of location in the brain and sampling down to a few mm. Although fMRI-based localisation does not suffer from the same type of uncertainties as EEG-based localisation as highlighted above, it is limited by other factors such as poor temporal resolution (of the order of seconds) and is subject to numerous artefacts (particularly at high field strengths such as 3T and above). Perhaps more impor-
...there are already signs that EEG-fMRI can provide additional information in the pre-surgical evaluation of patients with drug-resistant epilepsy.
Developing countries, where ~90% of the people with epilepsy reside, are least equipped to cope with the burden of care of these patients because of an unequal distribution of medical facilities and an inability of a major segment of the population to afford them. Nevertheless, during the last one and one-half decades, considerable progress has been made in the management of people with epilepsy in India. Investigational facilities such as electroencephalography (EEG), computed tomography (CT) and magnetic resonance imaging (MRI) scans are available in most major cities. Antiepileptic drugs (AEDs), including several of the new ones are widely available. Over 1500 surgeries for medically refractory epilepsy have been performed during the last 10 years, which is several fold more than those undertaken during the previous 50 years.

The burden of epilepsy

Recent community-based surveys have shown that epidemiological indices of epilepsy in India are comparable to those from developed countries, with a prevalence rate of ~5 per 10000 and incidence rate of ~50 per 100,000. With around 1000 neurologists and ~5 million people with epilepsy in India, there would be approximately 1 neurologist to take care of ~5000 persons with epilepsy. While 70% of the Indian population resides in rural areas, nearly all neurologists practice at or close to big cities and towns. A majority of people with epilepsy in India are therefore managed by primary and secondary care physicians with very little knowledge of the present day management of the epilepsies. In general, patients in India pay for medical care from their own resources. Epidemiological studies from rural parts of India have found that the medical treatment gap, which is defined as the proportion of persons with active epilepsy in the population who have never received AED treatment, is around 70%. Lack of medical facilities, failure to diagnose epilepsy, reluctance on the part of the patient and family to accept the diagnosis, and non-availability or non-affordability of AEDs contribute to this enormous treatment gap among the rural population.

Geographically specific epilepsy syndromes

Two epilepsy syndromes, hot water epilepsy and single small enhancing CT lesion in patients presenting with new onset focal seizures, are almost unique to India.

Hot water epilepsy

A reflex epilepsy precipitated by the act of pouring hot water over the head occurs almost exclusively in certain geographical regions of the south Indian state of Karnataka. The seizures are usually complex partial, characterized by a sense of fear, dazed look, visual or auditory hallucinations, and limb automatisms with or without secondary generalization. A positive family history is found in one-fifth of patients. The role of an aberrant thermoregulatory system sensitive to rapid increases in temperature, coupled to a genetic susceptibility for this disorder is currently being investigated. The majority of patients remit spontaneously within few years, but spontaneous non-reflex seizures may develop in a quarter of patients. Clobazam taken orally 1-2 hours before a hot water bath has been shown to be effective in preventing the reflex seizures.

Single small enhancing lesions

Although cerebral cysticercosis is widely prevalent in several parts of the world, a single cyst seen as a small ring-enhancing CT lesion in patients presenting with new onset focal seizures, occurs almost exclusively in India. Whether this is related to low parasite load or enhanced immune status of the host is uncertain. While the majority of lesions resolve spontaneously within 3 to 6 months without any specific treatment, some may calcify leading to chronic partial epilepsy. Treatment with a single standard AED is recommended for a period of 6 months or till the lesion disappears. The role of cysticidal drugs is controversial; albendazole was not found to be beneficial in one double-blind randomized placebo-controlled study.

Diagnostic facilities

Technical standards of EEG recording and interpretation are generally poor in India because of the lack of qualified technicians and adequately trained electroencephalographers. Widespread availability of MRI in recent years has resulted in its indiscriminate usage. Many of the MRIs performed outside the selected tertiary epilepsy referral centers in India do not conform to the required technical standards and are often performed without proper indication.

Treatment of the epilepsies

Medical treatment

Among the standard AEDs, only phenobarbitone is provided free of cost to patients through government dispensaries. Most new AEDs such as lamotrigine, topiramate, levetiracetam, and zonisamide are available and widely promoted by pharmaceutical companies among primary and secondary care physicians, whose knowledge about pharmacotherapy of epilepsy is limited. This frequently results in indiscriminate treatment with these expensive AEDs in patients who cannot afford them. Unnecessary AED polypharmacy is widely prevalent. In a study conducted at a tertiary referral center, 58% of the 972 patients referred from primary and secondary care facilities were receiving multiple AEDs simultaneously at the time of referral.

More than 95% of these patients were on inadequate dosages of the AEDs. Over the next two years, 72% of them were converted to monotherapy, with better seizure control, fewer side effects and reduced expenditure.

Surgical Treatment

Although the majority of patients with epilepsy are
responsive to presently available AEDs, nearly 30% of them continue to exhibit recurrent seizures, despite optimal AED therapy, resulting in reduced quality of life and substantially increased risk of morbidity and mortality.10 Epilepsy surgery is a useful option in selected patients with AED-resistant focal epilepsies.

The first epilepsy surgery in India was performed in 1951 by Dr Jacob Chandy at the Christian Medical College, Vellore.2 During the last 10 years, there has been a revival of interest in the surgical treatment of epilepsies, with a few major centers regularly performing epilepsy surgery. Over 850 epilepsy surgeries have been undertaken at the R. Madhavan Nayar Center for Comprehensive Epilepsy Care, Trivandrum, during the last 12 years, nearly three-quarters of them for refractory temporal lobe epilepsy. The majority of patients are selected for surgery based on non-invasive selection strategies at an affordable cost without compromising patient safety and seizure outcome.11 Those medically refractory epilepsy patients who are not candidates for resective epilepsy surgery, can be offered vagal nerve stimulation or a ketogenic diet. While the cost of vagus nerve stimulation can be afforded only by a minority of patients, there are very few centres in the country practicing ketogenic dietary management.

Some social issues
Misunderstanding and lack of knowledge about epilepsy and the resultant discrimination against people with epilepsy are still widely prevalent in India as in any other developing country. Since it is difficult for a woman with epilepsy to get married, parents often conceal the history of epilepsy at the time of marriage negotiations.12 Preliminary data from the Kerala Registry of Epilepsy and Pregnancy revealed that nearly two-thirds of the women were not receiving folic acid supplementation at the time of conception and congenital fetal malformations occurred at a frequency of about 13%.13

Conclusions
While tremendous progress in diagnosis and treatment of persons with epilepsy has been made in India in recent years, the distribution of epilepsy care is lopsided and concentrated in urban areas. More equitable distribution of services can be achieved by establishing more comprehensive epilepsy programs in different parts of the country to reduce the medical and surgical treatment gap, and to educate the public and primary health care providers about recent trends in the management of epilepsies.

References

She can remember her sodium valproate for epilepsy now that it’s once-a-day

- New Episenta is indicated for the treatment of epilepsy
- Episenta gives an advanced multi-unit delivery of sodium valproate
- Simple once daily dose for improved compliance
- Mini-tablets may be sprinkled onto soft foods or taken with drinks
- Convenient and easy to swallow, even for young children
Management of Chronic Migraine

Migraine is one of the commonest neurological disorders, and yet remains relatively underdiagnosed and undertreated. The World Health Organisation considers a day with severe migraine to be as disabling as tetraplegia, and estimates suggest that disability due to migraine costs over €27 billion per annum across Europe. A significant minority of migraine sufferers go on to develop chronic headache; this group constitutes an estimated 2-3% of the general population.

Chronic migraine was introduced as a diagnostic subcategory of migraine in the second edition of the International Classification of Headache Disorders (ICHD-2), and describes a chronic daily headache (by definition, occurring more than fifteen days per month), occurring in patients who have met the diagnostic criteria for migraine. The introduction of this classification prompted debate about the diagnostic criteria required in this (often complicated) patient group, which in turn has led to the publication of a revised set of criteria (Table 1). The term “chronic migraine” is a descriptive one, suggesting a significant ongoing headache burden, and is a useful standardisation for research purposes, but it should be recognised that it represents an arbitrary distinction. Patients with chronic migraine are often very significantly disabled by their headaches, form a significant part of general neurology and subspecialty headache practice, and constitute an ongoing therapeutic challenge.

By the time patients with chronic migraine reach neurology or headache clinics, their headaches may have been present for months, years or even decades. There may be a preceding history of episodic migraine, with or without aura, which gradually became more frequent over time. By the time such patients are seen at clinic, they have often been on a variety of medications and are often overusing acute therapies such as simple or compound analgesics and triptans. They may describe different headache types, not all with migrainous features, and tension-type headache and medication overuse headache may often coexist in such patients.

The first step towards effective treatment in chronic migraine is identification of factors which can contribute to headache chronicity, including medication overuse, co-administration of medications (such as nitrates) which may exacerbate migraine, and consideration of other medical factors (obstructive sleep apnoea, intracranial hyper- or hypotension or other causes of secondary headache) which may coexist. If there has been a recent or abrupt change in headache severity, character or pattern without apparent cause, consideration should always be given to the possibility of secondary headache.

Several studies have identified factors including attack frequency, medication overuse, head injury, female sex, obesity, hypothyroidism, snoring, stressful life events and low socioeconomic status as risk factors associated with the progression from episodic to chronic migraine. These, of course, may not be causative, and no interventional studies have been carried out as yet to assess the effects of modifying these factors on headache chronicity. It has been shown, however, that obesity is not in itself associated with refractoriness to treatment.

Although the ICHD criteria for chronic migraine specifically exclude concomitant medication overuse, in clinical practice the two frequently coexist. Patients who have found an analgesia regime that has worked well for previously infrequent episodic headaches understandably come to use these medications more often as their headaches become more frequent. When this occurs with any delay in initiating preventative therapy, or reluctance to take preventative treatment due to anticipated or actual side-effects, this situation may escalate to daily or near-daily usage of analgesia and/or triptans, even though the patient may offer that “the medication doesn’t really help, but I need to take it every day anyway”. The revised ICHD criteria define medication overuse as usage of ergotamine, triptans, opioids or combination analgesic medications on 10 or more days per month on a regular basis for more than 3 months. In addition, the revised criteria have acknowledged that patients taking simple analgesics or any combination of ergotamine, triptans, analgesics or opioids on 15 or more days per month, on a regular basis for more than 3 months, without overuse of any single class alone, also warrant a diagnosis of medication overuse.

The issue of how to optimally treat analgesia overuse in chronic migraine is one where received wisdom prevails without a strong evidence base. The traditional approach has been firstly to discontinue the overused medication where possible, or at least limit it to the recommended maximum frequencies above. This approach has been justified on the basis that medication overuse can in itself cause headache, as well as making the features of the underlying pain harder to characterise, and may interfere with the efficacy of preventative treatment.

Table 1: Revised International Headache Society criteria for chronic migraine

A. Headache (tension-type and/or migraine) on ≥15 days per month for at least 3 months

B. Occurring in a patient who has had at least five attacks fulfilling criteria for migraine without aura

C. On ≥8 days per month for at least 3 months headache has fulfilled C1 and/or C2 below, that is, has fulfilled criteria for pain and associated symptoms of migraine without aura

1. Has at least two of:
   (a) unilateral location
   (b) pulsating quality
   (c) moderate or severe pain intensity
   (d) aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs)
   and at least one of:
   (a) nausea and/or vomiting
   (b) photophobia and phonophobia
2. Treated and relieved by triptan(s) or ergot before the expected development of C1 above

D. No medication overuse and not attributed to another causative disorder

These pages are sponsored by Janssen-Cilag Ltd, makers of topiramate. Although this article was commissioned by Advances in Clinical Neurosciences and Rehabilitation, the authors received no payment for their work. The views expressed within this article are those of the authors, and not necessarily those of Advances in Clinical Neuroscience and Rehabilitation. Janssen-Cilag Ltd. Janssen-Cilag Ltd has exercised no editorial control over the content of this article.

The authors report no conflicts of interest.

Dr Paul Shanahan is a Locum Consultant Neurologist in the Headache Department at the National Hospital for Neurology and Neurosurgery, and specialises in the inpatient and outpatient management of headache disorders.

Dr Manjit Matharu is a Senior Lecturer and Honorary Consultant Neurologist at the Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London. His primary interests are the trigeminal autonomic cephalalgias, neurostimulation for medically intractable headaches, and functional and structural neuroimaging in primary headache syndromes.

Correspondence to: Dr MS Matharu, Headache Group, Institute of Neurology, Queen Square, London, WC1N 3BG, UK. Email. m.matharu@ion.ucl.ac.uk Fax. +44 (0)70 9212 0797.

Dr Paul Shanahan is a Locum Consultant Neurologist in the Headache Department at the National Hospital for Neurology and Neurosurgery, and specialises in the inpatient and outpatient management of headache disorders.

Dr Manjit Matharu is a Senior Lecturer and Honorary Consultant Neurologist at the Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London. His primary interests are the trigeminal autonomic cephalalgias, neurostimulation for medically intractable headaches, and functional and structural neuroimaging in primary headache syndromes.

Correspondence to: Dr MS Matharu, Headache Group, Institute of Neurology, Queen Square, London, WC1N 3BG, UK. Email. m.matharu@ion.ucl.ac.uk Fax. +44 (0)70 9212 0797.

The authors report no conflicts of interest.

Publication of this article has been made possible by sponsorship from Janssen-Cilag Ltd.
This final point in particular is open to dispute, as it lacks well-controlled supportive data. While there is a good empirical argument to be made for removing any potential contributory factors (i.e. overused medication) prior to initiating preventative treatment, in practice this may not be so easy. Patients withdrawing from abortive medications may experience an increase in headache among other symptoms which, although usually self-limiting, can test compliance and without adequate support, can result in relapse. Strategies for minimising relapse must centre on patient education: it is vital to discuss the treatment plan, explain what symptoms can be expected, that an increase in headache severity may occur initially and should be transient, and that a “wash-out” period will enable subsequent treatment to be directed at the patients truly underlying headache rather than a secondary, drug-induced one. Headache diaries kept during this period can help the assessment process. It is also important that the patient (and treating doctors) realise that all abortive medications when overused can exacerbate headache, to avoid the pitfall of substituting overuse of one agent for another.

Adjunctive therapy during the withdrawal period can be helpful in reducing discomfort and assisting compliance. It is our practice to use naproxen or similar long-acting NSAIDs (sparingly) to “take the edge off” headaches during the withdrawal period. In patients with significant tenderness over the greater occipital nerve, an injection of lidocaine and depot methylprednisolone over the nerve may provide a transient reduction in headache severity (typically lasting from two weeks) which can help to ease the withdrawal process. Some clinicians advocate the use of oral steroids during the withdrawal period, but a recent study of reducing doses of oral prednisolone (60mg tapering to zero over six days) did not show any reduction in rebound headache compared to placebo.6

Although many preventative drugs have been shown in placebo-controlled trials to be beneficial in episodic migraine, few studies have been conducted in chronic migraine. Treatment of chronic migraine, as with disabling episodic migraine, involves a combination of effective, abortive strategies in addition to a preventative agent such as those listed in Table 2.

Diener et al recently carried out a randomised, double blinded, placebo controlled trial of prophylactic topiramate in the setting of chronic migraine with and without medication overuse.7 They found that in the group as a whole, topiramate reduced the number of headache days per month by 3.5 ± 6.3, compared to an increase in the placebo group of 0.2 ± 4.7 (P=0.02). In the medication-overuse subgroup, topiramate reduced headache days per month by 3.5 ± 7.1 compared to an increase of 0.8 ± 4.8 with placebo (P=0.03). Although these figures are encouraging, there are a few caveats: the study was small, with 59 patients overall, 32 of whom received topiramate. Of these, only 23 were overusing medication. There was also a significant drop-out rate, with only 24 patients on topiramate completing the double-blind phase of the trial.

There were differences in the baseline patterns of medication overuse between the treatment and placebo groups: 30% of the topiramate group were overusing analgesia compared to 9% in the placebo group, whereas 96% of the placebo group were overusing triptans compared to 61% of the topiramate group. It is also interesting to note that the significant reduction in headache days did not translate into a significant reduction in usage of acute medications in either the group as a whole or the medication-overuse subgroup. It is difficult, therefore, to conclude with certainty that initiating preventative treatment prior to withdrawing analgesia will make subsequent withdrawal any easier, and in our practise we still make every effort to eliminate medication overuse prior to any other interventions. Hopefully, future studies will clarify this issue further.

The complications arising from analgesia and triptan overuse also make a strong case for patient education while headache is still episodic. Patients and doctors alike need to be aware of the importance of initiating preventative treatment for frequent headache, and to realise that excessive use of abortive therapy becomes part of the problem rather than the solution.

Table 2: Drugs used for prophylaxis in migraine

<table>
<thead>
<tr>
<th>Beta-Blockers:</th>
<th>Atenolol, Metoprolol, Propranolol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticonvulsants:</td>
<td>Sodium Valproate, Topiramate, Gabapentin</td>
</tr>
<tr>
<td>Antidepressants:</td>
<td>Amitryptiline, Nortriptyline, Doxepin, Venlafaxine, Phenelzine</td>
</tr>
<tr>
<td>Calcium Channel Blockers:</td>
<td>Flunarizine</td>
</tr>
<tr>
<td>SHITα2C antagonists:</td>
<td>Pizotifen, Methysergide</td>
</tr>
<tr>
<td>Others:</td>
<td>Coenzyme Q10, Riboflavin, Butterbur, Feverfew, Lisinopril, Candesartan</td>
</tr>
</tbody>
</table>

* Not all the agents in the above table are licensed for prophylaxis of migraine in the UK. Check individual Summaries of Product Characteristics (SPC) for more information regarding specific licensed indications for each agent prior to prescribing.

Effective treatment for chronic migraine can reduce overall disability but has other advantages too. Silberstein et al have shown, in the case of topiramate, that preventative treatment over a 12 month period reduced resource utilisation, with a 46% decrease in A&E visits, a 72% decrease in diagnostic procedures, a 61% decrease in hospital admissions, and a 35% decrease in visits to physicians, resulting in lower total healthcare costs compared with baseline, even allowing for the cost of treatment. One can therefore argue that aggressive treatment of troublesome migraine, with early intervention to avert chronicity if possible, together with avoidance of medication overuse and appropriate prophylaxis, benefits all those who deal with this common and disabling condition.

References
Neurobiology of Alzheimer’s Disease (3rd edition)

I recall buying the first edition of this book (produced by Bios Scientific Publishers) when I was a struggling research registrar in 1996. Over 10+ years and two further editions the book has expanded (now 30% larger by pages) but many of the topics remain as before: neuropathology, genetics, APP metabolism, amyloid β-peptide and its cellular targets, tau and neurofibrillary pathology, animal models of AD (but no mention of flies), inflammation, neurotransmitters, neurtrophins. These are comprehensive accounts, heavily referenced throughout, on subjects central to the endeavour of understanding AD pathophysiology. There is a new chapter on (CSF) biomarkers, and therapy now has two chapters, one exclusively on amyloid based therapies. The chapter on clinical assessment sits somewhat uneasily within the neurobiological milieu (and neurologists may blench to read that dysphasia is “difficulty with articulation of speech”, p335) and the chapter on neuroimaging has disappeared.

The preface points out that previous editions went to press just as significant new findings were breaking (linkage of familial AD to chromosomes 14 and 1 in 1995; characterisation of BACE in 1999), and it is possible that a similar thing has happened with this edition. Although sortilin is mentioned (p295) as a p75NTR binding part-

ner, it seems publication came too soon to include the recent excitement about a genetic association between the sortilin receptor SORL1 and AD (Rogaeva et al., Nat Genet 2007; 39: 168-77).

The scientific accent of the book means that a few clinical errors creep in: for example, FTDP is not “frontotemporal dementia of the Parkinson type” (p3), and the cerebellum is affected in AD (p235); there are well-described neuropathological and neurochemical changes.

Neurologists with an interest in dementia in general and AD in particular are presumably, following the 2006 NICE/SCIE guidelines, an endangered species threatened with extinction (PCTs and special health authorities apparently comprehend no role for neurologists in the management of this most quintessential of brain diseases), and so the principal market for this book will be amongst the growing numbers of neuroscientists with an interest in AD, and possibly those psychogeriatricians with more than simply a clinical interest. When one considers that the first edition cost me £65 in 1996, the current price of under £50 seems good value for money.

AJ Larner, Cognitive Function Clinic, WCNN, Liverpool, UK.

Including People with Communication Disability in Stroke Research and Consultation – A Guide for Researchers and Service Providers

A concise, practical guide drawing on the authors’ professional experiences of people with aphasia. Its aim is to increase inclusion in stroke research and consultation of people with communication disability. Aphasia is reported in 30% of first ever ischaemic stroke patients, whilst aphasic stroke patients tend to be older than their nonaphasic peers, thus confirming aphasia to be a very common and important problem with an age-related dimension. Improving inclusivity is of course particularly topical given the current emphasis on ‘user involvement’ in health care and research.

The authors are right to address the issue of communication impairment in this simple and accessible guide although perhaps an overly simplistic style in places will not appeal to everyone. It has been published by Connect, the communication disability network (www.ukconnect.org) – a national charity based in London promoting effective services, new opportunities and a better quality of life for people living with aphasia.

The guide comprises seven short chapters, a resource list, bibliography, and a forty-nine page appendix containing extensive examples of documents considered by the authors to be accessible to people with aphasia. The guide includes an elementary introduction to communication impairment, suggestions for improving inclusivity and practical strategies for effective interviews, meetings, and dissemination of information in the context of communication impairment.

Overall a highly practical publication which can be readily and quickly absorbed – hopefully it will achieve its stated aims.

Dr Hedley Emsley, Clinical Lecturer in Neurology, Division of Neuroscience, University of Liverpool, UK.


Encephalitis - a parent’s handbook

This guide to encephalitis in childhood is an extremely comprehensive, well thought out support for parents. The easy-to-read and thorough approach perfectly balances the complex scientific information necessary to make informed choices about the necessary services at the time of illness and following on into community care.

As a resource for dealing with the various sequelae and consequences of the illness, particularly with regards to potential behavioural difficulties and education, it is extremely useful for all members of an interdisciplinary team around the child.

It therefore fulfils its remit as a support tool for the child and family, but wider reading should be compulsory for all members of health, education and social teams that have dealings with children who have had encephalitis.

Charlie Fairhurst, Chailey Heritage Clinical Services, Lewes, UK.

Compiled by: Dowell, E. Published by: Encephalitis Society, 2006 www.encephalitis.info. Price: £10
Developments in medical and surgical care have led to improved survival following injuries that would previously have been fatal, and means that those suffering with severe brain injuries (GCS<8) are more prevalent in our hospitals and rehabilitation units. The use of generally agreed terminology for unresponsive patients will allow study populations to be described more consistently, and their implications to be generalised with more confidence. Functional MRI provides physiological evidence to support, or refute, clinical beliefs about patients’ awareness. Assessments should be repeated regularly, and reports of all those participating in the care of the patient, including family, should be noted. Prognostic decisions should be made by physicians and professionals with experience working in assessment of those with impaired consciousness.

Previous descriptions of the assessment and diagnosis of those in vegetative and minimally conscious states can be found in earlier editions of this journal. It is imperative that diagnosis is accurate and secure as this will affect decisions about rehabilitation potential and therefore the level of rehabilitation input. The question of where patients should go for further rehab or long-term care must be considered by the whole team. The importance of therapist input to this process has been recognised but, until recently there has been little evidence of effectiveness of rehabilitation in this patient group.

Early rehabilitation is accepted as having positive effects upon facilitating patient recovery. Active therapy may reduce their stay in the critical care unit and avoid the secondary effects of spasticity and contractures, which will reduce cost of care overall. Critical care units that have a therapeutic ethos can start observations of patients in low arousal states, and information about timing of emergence from coma has useful prognostic value. The Glasgow Coma scale is not sensitive enough to detect change within this group, and more specific measures have been developed for this purpose: the Sensory Modality Assessment and Rehabilitation Technique (SMART), the JFK Coma recovery scale and the Wessex Head Injury Matrix (WHIM). In our experience the WHIM is sensitive to subtle behaviour changes and is easy for staff to learn to administer. Therapists may observe behaviours in response to passive movements as part of respiratory management or maintaining joint range of movement. Often, rolling a patient is enough to stimulate some eye opening, or other behavioural response previously un-witnessed. This is presumed to be due to activation of the reticular system by patient movement. These passive movements are usually accompanied by verbal or visual stimuli, which may provoke some responses. Positioning of the patient with a neutral and well supported posture will reduce tone and aid comfort, but also augments the potential for interaction as active movement is more readily accessible.

Gradually standing patients from horizontal to vertical on a tilt table enhances visual stimuli, stretches calf muscles, and is thought to reduce loss of bone density. Tilt tabling also offers a number of key benefits to the assessment and therapeutic stimulation of patients with impaired consciousness. Pilot work by Elliott et al found that standing patients using a tilt table revealed behaviours not observed in the supine position. This effect was significant in both vegetative and minimally conscious patients. However, the behaviours observed in vegetative patients remained reflexive and the act of standing patients did not reveal behaviours suggestive of awareness of self or environment.

We have now documented the outcome of tilt tabling in minimally conscious patients. This research has been developed with the support of Dr Coleman, Mrs Baker (nee Elliott), Dr Shiel, Professor Wilson and Professor Pickard.

**Results:**

<table>
<thead>
<tr>
<th></th>
<th>VS Patient Group</th>
<th>MCS Patient Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highest ranked behaviour</td>
<td>Supine</td>
<td>Elevated</td>
</tr>
<tr>
<td>Total number of behaviours</td>
<td>Supine</td>
<td>Elevated</td>
</tr>
</tbody>
</table>

**Standing Enhances the Behavioural Repertoire of Minimally Conscious and Vegetative State Patients**

Katharine Symons, BSc (hons) is a senior neuroscience physiotherapist working clinically in the regional head injuries unit within Cambridge University Teaching Hospitals NHS Foundation Trust and also in collaboration with the Cambridge Impaired Consciousness Study Group. Interests include the acute management of head injured patients, specifically those within the vegetative or minimally conscious state.

Correspondence to:
Katharine Symons,
Addenbrookes NHS Trust,
Physiotherapy Department – Box 185,
Hills Road,
Cambridge,
CB2 2QQ
Email: katharine.symons@addenbrookes.nhs.uk

Acknowledgements
This research has been developed with the support of Dr Coleman, Mrs Baker (nee Elliott), Dr Shiel, Professor Wilson and Professor Pickard.
a total of 24 patients (11 VS, 13 MCS, 15 male, average age 44, range 19-71; 11 TBI) in terms of the behaviours observed in the supine and standing position. These results incorporate the 12 patients in Elliott et al., 2005. Patients were assessed whilst lying in bed, during a 20-minute stand in a tilt-table at 85°, and again whilst lying in bed. The patient’s behaviour was assessed using the WHIM. These observations were repeated over a one-week period, at 6 & 12 months post ictus, and the median highest ranked behaviour and median total number of behaviours observed, were recorded (Table 1).

Eleven patients (3 VS and 8 MCS) showed greater highest ranked behaviours (p=0.004) and total number of behaviours (p=0.001) in the standing position (Figures 1 and 2). Twelve patients (8 vegetative and 4 minimally conscious) showed no change and one minimally conscious patient showed a one point decrease in the highest ranked behaviour in standing. Although WHIM scores in 3 vegetative patients increased during standing, the behaviours observed did not reach a level suggesting increased awareness of self and/or environment. WHIM observed did not reach a level suggesting consciousness of self and/or environment. WHIM scores in the second supine period were the same or lower than in the first. This study demonstrates that simple interventions can enhance behavioural repertoire in some low awareness patients, and that consistent use of the WHIM can help identify changes over short periods of time. Making all nurses, therapists and staff aware of the sorts of changes over short periods of time. Nurses and raising interest in the active management of this group of patients.

### Table 1: Highest ranked behaviours recorded in the supine and standing positions for each patient. Patient classification at the time of recruitment is denoted VS (vegetative state) or MCS (minimally conscious state).

<table>
<thead>
<tr>
<th>Patient</th>
<th>VS / MCS</th>
<th>Supine highest ranked score</th>
<th>Behaviour observed</th>
<th>Standing highest ranked score</th>
<th>Behaviour observed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>VS</td>
<td>6</td>
<td>Volitional vocalisation to express feelings</td>
<td>6</td>
<td>As Supine</td>
</tr>
<tr>
<td>2</td>
<td>VS</td>
<td>43</td>
<td>Smiles</td>
<td>43</td>
<td>As Supine</td>
</tr>
<tr>
<td>3</td>
<td>VS</td>
<td>4</td>
<td>Attention held by dominant stimulus</td>
<td>4</td>
<td>As Supine</td>
</tr>
<tr>
<td>4</td>
<td>VS</td>
<td>43</td>
<td>Smiles</td>
<td>43</td>
<td>As Supine</td>
</tr>
<tr>
<td>5</td>
<td>VS</td>
<td>5</td>
<td>Looks at person briefly</td>
<td>26</td>
<td>Frowns, grimaces etc. to show dislike</td>
</tr>
<tr>
<td>6</td>
<td>VS</td>
<td>1</td>
<td>Eyes open briefly</td>
<td>49</td>
<td>Vocalises to attract attention</td>
</tr>
<tr>
<td>7</td>
<td>VS</td>
<td>14</td>
<td>Mechanical vocalisation (yawn, sigh)</td>
<td>26</td>
<td>Frowns, grimaces etc. to show dislike</td>
</tr>
<tr>
<td>8</td>
<td>VS</td>
<td>1</td>
<td>Eyes open briefly</td>
<td>1</td>
<td>As Supine</td>
</tr>
<tr>
<td>9</td>
<td>VS</td>
<td>14</td>
<td>Mechanical vocalisation (yawn, sigh)</td>
<td>14</td>
<td>As Supine</td>
</tr>
<tr>
<td>10</td>
<td>VS</td>
<td>45</td>
<td>Smiles</td>
<td>43</td>
<td>As Supine</td>
</tr>
<tr>
<td>11</td>
<td>VS</td>
<td>24</td>
<td>Maintains eye contact over 5 seconds</td>
<td>24</td>
<td>As Supine</td>
</tr>
<tr>
<td>12</td>
<td>MCS</td>
<td>57</td>
<td>Names or indicates left and right on self</td>
<td>57</td>
<td>As Supine</td>
</tr>
<tr>
<td>13</td>
<td>MCS</td>
<td>13</td>
<td>Looks at person giving attention</td>
<td>16</td>
<td>Turns head/eyes to look when someone is talking</td>
</tr>
<tr>
<td>14</td>
<td>MCS</td>
<td>20</td>
<td>Vocalises to express mood or needs</td>
<td>36</td>
<td>Switches gaze from one person to another, spontaneously</td>
</tr>
<tr>
<td>15</td>
<td>MCS</td>
<td>26</td>
<td>Frowns, grimaces etc. to show dislike</td>
<td>34</td>
<td>Monosyllabic or single words in response to questions</td>
</tr>
<tr>
<td>16</td>
<td>MCS</td>
<td>26</td>
<td>Frowns, grimaces etc. to show dislike</td>
<td>26</td>
<td>As Supine</td>
</tr>
<tr>
<td>17</td>
<td>MCS</td>
<td>15</td>
<td>Performs physical movement on verbal request</td>
<td>14</td>
<td>Mechanical vocalisation (yawn, sigh)</td>
</tr>
<tr>
<td>18</td>
<td>MCS</td>
<td>18</td>
<td>Tracks for 3-5 seconds</td>
<td>28</td>
<td>Looks at object when requested</td>
</tr>
<tr>
<td>19</td>
<td>MCS</td>
<td>8</td>
<td>Makes eye contact</td>
<td>23</td>
<td>Shows selective response to preferred people</td>
</tr>
<tr>
<td>20</td>
<td>MCS</td>
<td>42</td>
<td>Can find a specific playing card</td>
<td>43</td>
<td>Smiles</td>
</tr>
<tr>
<td>21</td>
<td>MCS</td>
<td>12</td>
<td>from a selection of four</td>
<td>24</td>
<td>Maintains eye contact over 5 seconds</td>
</tr>
<tr>
<td>22</td>
<td>MCS</td>
<td>26</td>
<td>Frowns, grimaces etc. to show dislike</td>
<td>26</td>
<td>As Supine</td>
</tr>
<tr>
<td>23</td>
<td>MCS</td>
<td>52</td>
<td>Uses one or two gestures</td>
<td>52</td>
<td>As Supine</td>
</tr>
<tr>
<td>24</td>
<td>MCS</td>
<td>33</td>
<td>Seeks eye contact</td>
<td>43</td>
<td>Smiles</td>
</tr>
</tbody>
</table>

**References**

More than 5000 neurologists from 75 countries around the world attended the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) to hear the latest research in the field, ranging from the basic science of MS to highly sophisticated innovations with targeted new drugs and detailed scanning techniques. The meeting was held in the Czech capital of Prague, a city combining historical buildings and squares with modern transport and facilities to meet the challenges of a 21st European centre.

In the opening lecture of the congress, Christian Confavreux, Hopital Neurologique Pierre Wertheimer, Lyon, France, underlined the importance of collaborative work between Europe working together with collaborative databases and large cohorts of MS patients to make progress. He suggested that these efforts had resulted in major advances in understanding over the past decade, including the influence of pregnancy on the course of the disease and the risk of relapse following vaccination. Professor Confavreux considered that there was now good evidence that relapses in MS are the clinical counterpart of acute focal inflammation of the central nervous system while progression is that of chronic diffuse neurodegeneration. He questioned whether MS should be considered as a primary autoimmune disease or as a primary degenerative condition. Late pathological studies have shown the presence of activated microglial-like inflammatory cells disseminated in the CNS. “In other words, diffuse neurodegeneration is likely to be related to inflammation, even if the latter is not autoimmune,” he proposed. Assuming this pathogenetic picture was well founded, he told delegates, “Treating the acute focal inflammation is not enough. One must fight against the silent diffuse inflammation nested in the central nervous system beyond the blood-brain barrier. This is the new challenging frontier in MS treatment.”

**Study confirms Epstein-Barr virus associated with MS**

Patients with MS have higher levels of Epstein-Barr virus (EBV) DNA than healthy controls and viral load fluctuates with disease activity, according to a study reported at the congress.

The study measured levels of EBV DNA in peripheral blood leukocytes from 112 patients with stable, relapsing remitting (RR) MS, 28 at the onset of a clinical relapse of RRMS, and 39 controls, using quantitative PCR for the BamHIW repeat and the LMP2a gene. Results showed a trend to higher viral loads in the MS patients. The median number of copies of BamHIW per million cells was 59 for controls, 91 for patients with stable RRMS and 102 for patients in relapse. The corresponding values for LMP2a were 0, 10.6, and 9.8. Although the range of values in the three groups overlapped, the differences approached statistical significance for the comparison of LMP2a in controls and patients with stable MS (p=0.068, rank sum test).

Fourteen of the patients had blood collected both during a relapse and while stable. Their levels of EBV DNA were increased during relapse in six of them, unchanged in six and decreased in two.

The researchers, led by J William Lindsey, Associate Professor in Neurology at the University of Texas, Houston, USA, said, “Our assay sensitivity was excellent and detected EBV DNA in the majority of subjects. There is a trend towards increased viral loads in MS patients and a suggestion that viral load may fluctuate with clinical disease activity.”

A second, Norwegian Study showed that all 61 patients with RRMS tested were positive for a marker of previous EBV infection, anti-VCA IgG, while 98% were positive for a second marker, anti-EBNA IgG. However, there was no association between disease activity and EBV reactivation. A third study reported at the congress was consistent with EBV acting as a trigger of MS, with a higher level of activation of EBV-specific CD8+ T cells in patients with early MS.

Multiple Sclerosis 2007;13:484, P483, P485

**Study suggests FTY720 may repair MS damage by direct effect on brain**

Encouraging findings were reported with several new agents, including a study showing that FTY720 (fingolimod), an oral sphingosine-1-phosphate receptor agonist, acts directly on the central nervous system (CNS) to reduce disease severity in addition to peripheral effects on the immune system.

The study in experimental autoimmune encephalomyelitis showed that administering FTY720 directly into the CNS significantly reduced disease severity. This occurred even though there was no reduction in lymphocytes in the bloodstream, indicating that the agent has a direct effect in the CNS that is independent of its effects on peripheral lymphocytes. When FTY720 is given orally, it stops lymphocytes leaving peripheral lymph nodes and infiltrating the CNS, which is another important part of its action in MS.

Howard Weiner, Professor of Neurology at Harvard Medical School, Boston, USA, said: “MS is a disease affecting the central nervous system – but most of the drugs we currently have act peripherally. These results suggest that the mechanism of action of FTY720 may involve CNS-mediated effects, in addition to reducing T-cell infiltration into the CNS. This raises the possibility that it might also have protective effects in progressive stages of the disease.”

A further study showed that FTY720 increased the number, growth and survival of oligodendrocytes – the cells that make myelin, which insulates nerve fibres and is damaged in MS - in cell culture. This effect could potentially limit destruction of myelin and promote its repair, which could contribute to the effectiveness of FTY720 in MS.

Results from a phase II study in 281 patients with relapsing MS (the commonest type) showed that once-daily, oral FTY720, reduced relapse rates by more than 50% after six months, compared to placebo. It also reduced magnetic resonance imaging (MRI) measures of inflammation, with around 80% of patients free of active brain lesions. In patients continuously treated with FTY720 for up to two years, up to 77% remained relapse-free and more than 80% were free of active brain lesions at two years.

Commenting on the findings, Gavin Giovannoni, Professor of Neurology at Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, said, “In the emerging therapies, FTY720 is interesting because of its mode of action – with results showing that it may act centrally to provide neuroprotection, as well as having effects on the immune system. The availability of an oral drug would change the face of MS treatment completely.”

23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

11-14 October, 2007; Prague, Czech Republic.
Positive results were also reported with rituximab, a monoclonal antibody that selectively depletes CD20+ B cells. A double-blind, controlled trial randomising 104 patients with RRMS to intravenous rituximab (1000mg) or placebo on days 1 and 15 showed a significant reduction in gadolinium (Gd) enhancing lesion counts at weeks 12, 16, 20 and 24 (mean 0.5 vs 5.5 with placebo, equating to a 91% reduction; p<0.0001). There was also a reduction in new Gd-enhancing lesions and in relapses. Infusion-associated adverse events affected more than three-quarters (78.3%) of patients given rituximab.

A study in 45 patients with active RRMS who had failed beta-interferon treatment showed that alemtuzumab, a humanised monoclonal antibody targeting the CD52 antigen expressed predominantly on lymphocytes, achieved a 9.3 fold reduction in relapse rate in the two years after treatment compared to the two years previously (p<0.0001). Most patients (70%) also had stable or improved Multiple Sclerosis Functional Component scores at two years. Alemtuzumab was generally well tolerated, although four cases of autoimmune thyroid disorder and one case of transient thrombocytopenia occurred. Professor Giovanni considered the efficacy results were ‘remarkable.’

Multiple Sclerosis 2007; 13: P484, P554, P558

Summing up the new developments at the meeting, Gavin Giovanni considered studies reported at ECTRIMS with some of the newer agents had shown particularly promising results for the future. He suggested that the results seen with FTY720 were interesting, particularly because of the potential for activity in the central nervous system, and for neuroprotection. The phase 2 study results with rituximab also looked very interesting, in addition to the data reported with BG-12, laquinimod and cladribine.

Focusing on patients’ needs, Professor Giovanni thought that the development of oral therapies was the most pressing issue. “The introduction of effective oral treatment will change the face of treatment completely,” he said. With moves to diagnose MS earlier, he predicted that earlier treatment would become standard. “It is beyond doubt that we should treat earlier, as the damage starts from an early phase of MS – so we need treatments that patients can use earlier easily, effectively and safely.” He hoped that the next couple of years would see further positive data.

Susan Mayor PhD, Freelance Medical Journalist, London, UK.

Neurosocieties: The Rise and Impact of the New Brain Sciences

12-13 November, 2007; London, UK.

The launch meeting of the European Neuroscience and Society Network was held in the comfortable and attractive Darwin Building at Regent’s College Conference Centre, within the beautiful setting of Regent’s Park, London on 12th and 13th November 2007. Professor Nikolas Rose, sociologist and Director of the BIOS Research Centre (for the study of Biosciences, Biomedicine, Biotechnology and Society) at the London School of Economics, welcomed a broad mix of specialists from the fields of neuroscience (neuroanatomy, clinical neuroscience, neuropsychology etc) and the social sciences (sociologists, psychologists and anthropologists etc) to this bold venture in interdisciplinary discussion of the political, ethical and social implications of ‘the new brain sciences’. Rose spoke of ‘setting an agenda for Europe’, in terms of discovering ‘what’s going on’, noting major differences between countries, and also ‘what’s going on in different fields’, getting the picture from, say, clinicians, imagers, psychiatrists and neuroscientists.

‘Public health and the politics of the neurosciences’ was the theme for the opening plenary. ‘The challenges of regulating neuropharma- cology’ were outlined with lively and controversial examples by Simon Gregor (Director of Communications), stepping in for Professor Kent Woods (CEO) to speak about their work at the Medicines and Healthcare Products Regulatory Agency. The UK regulators’ view was juxtaposed with the concerns of the clinician, Professor Matilde Leonardi, Consultant Neurologist (adult and paediatric), from the Neurological Institute Carlo Besta, Italy, speaking of ‘Neurosciences and neuropolitics: two challenges for brain disorders.’ ‘Maybe neurological patients do not get their voices heard: your GPs do not allow patients to get to neurologists’, but, “these disorders are at the top of the patients’ agenda”. Substantiating her arguments initially with figures from 28 European countries, Leonardi then challenged us to look afresh at statistics and their very conceptualisation towards a count of ‘years lived with disability’, which added to length of life, produce the measure: ‘Disability Adjusted Life Years’ (DALY). On this basis, ‘neurological conditions count for 50% of all diseases in Europe… therefore, investment is not yet compatible with the impact of neurological disease’. (see ‘Measuring Health and Disease in Europe’ at www.mhadie.it).

Rose, chairing this first plenary, raised three issues:

- that psychiatric and brain trauma had been brought together in Leonardi’s figures;
- that the word ‘burden’ (used in reference to the amount of disease) is ‘a term contested by survivors’;
- the terms ‘disability’ versus ‘disease’, how to reconcile this?

Here was an indication of the plunge pool of battles over words that the ENSN will encourage in its bringing together of embodied medical and social thought! Leonardi cooly and robustly defended her use of language before Rose proceeded to gather in questions of a diverse nature from the audience, which Gregor and Leonardi addressed. Ample time was arranged for these discussions within each plenary, and in the breaks for refreshments, delicious lunches and the splendid conference dinner, intensely interesting debates continued.

Each of the four plenaries was planned on a similar model, with two speakers from different disciplinary backgrounds presenting, a stimulus to lively question and answer sessions, for example:

‘Sources of the Neurochemical Self: consciousness, personhood and difference’ Professor Alexandre Mauron, University of Geneva ‘The neurochemical self and social inequality: a new face of neuroethics’ Dr Ilinna Singh, BIOS Centre, LSE. ‘Theories of personhood: self, brain and behaviour in boys with ADHD’.

The third session on 11th November was ‘Neuroeconomies: markets, choice and the distribution of neurotechnologies’, in which their global development and production was stunningly illustrated by the first speaker, Zack Lynch, Executive Director of the Neurotechnology Industry Organization. A discursive note on ‘The birth of neuroeconomy’ by Dr Philippe Pignarre, University of Paris, followed as counterpoint. The final plenary, to close the meeting on 12th, was ‘Neuroscience and Society: Future Directions in Europe’ after a morning spent in selected discussion workshops relating to the four plenary themes.

The interdisciplinary exchanges between life scientists and social scientists, from this and subsequent ENSN conferences and workshops (in Europe and North America), will be published in a series of annual volumes in international journals. Additionally, the network will provide exchange and travel grants to junior scholars in the field. The project is funded by the European Science Foundation to run from June 2007 to June 2012.

Further information:
www.esf.org/ensn
www.neurosocieties.eu

Richenda Power PhD, Writer, member of the London Freelance Branch of the National Union of Journalists.
Association of British Neurologists’ Autumn Conference

14–16 November, 2007; London, UK.

What’s New?

Historically, the ABN meeting comprised single sessions, from Wednesday lunchtime to Friday afternoon, including a mixture of basic science and clinical research presentations, and lectures from invited experts. However, with increasing numbers of attendees representing an ever-wider range of interests a number of innovations premiered this year including parallel sessions and dedicated teaching sessions. Although biased because one of the ABNT posters featured, I thought the expert led poster session was excellent, allowing lots of questions in an informal setting.

Teaching

In common with other meetings, the teaching role of ABN meetings is increasingly recognised, and the first session this year was a practical session on neuro-ophthalmology, led by Dr Gordon Plant and Prof Chris Kennard. This covered a wide range of practical aspects of ophthalmology as relevant to the neurologist.

Parallel Sessions

Two sessions were run at once on days one and two of the meeting, allowing for a greater spread of specialist interest. Although all presentations were of extremely high quality, several stood out as excellent. Although all presentations were of extremely high quality, several stood out as excellent.

- Confocal retinal microscopy for idiopathic small fibre sensory neuropathy. It appears sensitive, quick, and does not require a neurophysiologist (Pitcaithly).
- The spectrum of neuro myelitis optica includes brain stem dysfunction at presentation. The aquaporin 4 antibody test offered at Oxford appears to be more sensitive than the original NMO IgG antibody (Viegas). Why?
- Axonal loss in MS may be related to acid sensing ion channel 1. Craner showed results from genetic knock-out models, and small molecule inhibition with amiloride. Amiloride is a partial blocker that was effective even when given after onset of experimental autoimmune encephalomyelitis (EAE). Targeting the acid sensing channel 1 on immune cells had no effect.
- Biomarkers of neurodegeneration continue to be sought. The use of Diffusion Tensor Imaging (DTI) in PD was highlighted by Bajaj and Positron Emission Tomography (PET) using amyloid and microglial markers in AD by Okello.

Guest Lectures

As usual, the guest lectures (this time all on day 2) were of very high quality.

Raymond Tallis talked eloquently on the evolution of man, with relevance to the importance of the hand. An infinite array of movement was made possible by the move to bipedal locomotion in early humans. The hand, freed from locomotor tasks, became a “proto-tool”, driving consciousness and ultimately to the evolution of a self-aware homo sapien. Tallis argued that ‘man’ is now free from the constraints of nature and biology that define the existence of all other life-forms on this planet. Whilst thought provoking, it is hard to cover this topic in 1 hour, with unavoidable gaps in the story. There is evidence of tool use from over 5 million years ago, followed by little evolutionary or societal change, but in the last 100,000 years language, technology and sociology have developed in an exponential fashion. Unanswered questions include:

1. Why did Homo sapiens come on to the scene so late and then become so successful?
2. Why did Neanderthals (and other hominids) fail to survive? Did they have subtly different hands, or were they just unlucky?

Richard Wise reviewed modern tractography and connections between Broca’s area, Wernike’s area, area 39, and the anterior temporal lobe. He presented evidence from fronto-temporal dementia subjects with semantic and anomic deficits, as well as functional MRI and tractography from different animal models which although unable to produce language have excellent audiological cortices. Parallels between these two models were discussed, and an over-riding theory of language dysfunction explored.

Industry sponsored sessions

The success of ABN meetings is in part thanks to the industry sponsors. Without their hard cash, the meetings (in their present form) would be uneconomic. One of the sponsored sessions was especially interesting.

Novel Therapeutic Agents: The challenges of Adoption in the UK

The decisions (and consequences thereof) made by NICE on both acetylcholinesterase inhibitors (for treatment of dementia) and Natalizumab (Tysabri, for the treatment of inflammatory disorders including Multiple Sclerosis) were reviewed. Data they presented showed that the UK is slower to use novel therapies than other countries, and that neurologists may be particularly slow to use them, compared with other medical specialties. Professor Isaacs reported data from questionnaire-based research (Programme Identifying and Observing Novel Therapy Adoption in Chronic Diseases: PIONEER), which compared neurologists to rheumatologists, in the treatment of Multiple Sclerosis (MS) compared with Rheumatoid Arthritis (RA). Rheumatologists are more aggressive in their treatment choices, and far more of them support early treatment in RA compared with neurologists treating MS. Are neurologists more cautious? The rheumatologists said the ‘tipping point’ came when they accepted that RA was fatal, and that early joint damage was irreversible. The parallels to MS are striking. A Norwegian doctor asked whether we just don’t have enough neurologists to treat and to act as advocates for our patients. If neurologists looked after patients with late complications of MS (such as urinary tract infection or aspiration pneumonia) then would we be more aware of the long term consequences of chronic neurological disorders? Would having enough neurologists to do all this change the nature of a UK neurologist?

ABNT forum

I would like to thank those trainees who got up early on Thursday morning to come to our forum. We would also like to thank all trainees that returned our questionnaires, which have allowed us to provide high quality data to support trainees’ views on MMC and other issues.

The Tooke review was discussed, and its radical proposals (including an end to run-through training) were generally welcomed by trainees (Table 1). However, the transitional years of 2008–9 will be more competitive than 2007, due to under-provision of training posts, and mishandled transition mechanisms.

<table>
<thead>
<tr>
<th>Table 1: Key points from the draft Tooke Report</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Principles of broad-based, flexible training and aspiration to excellence</strong></td>
</tr>
<tr>
<td><strong>Criticism of policy development and governance and current mechanisms for workforce planning</strong></td>
</tr>
<tr>
<td><strong>Streamlining of regulation – PMETB to become part of the GMC</strong></td>
</tr>
<tr>
<td><strong>Changes to structure of post-graduate training</strong></td>
</tr>
<tr>
<td>- Foundation year 2 to be abolished</td>
</tr>
<tr>
<td>- 3 year basic specialist training programmes</td>
</tr>
<tr>
<td>- Competitive entry to higher specialist training programmes</td>
</tr>
<tr>
<td><strong>Possible distinction between post-CCT specialists and consultants with additional selection at this point</strong></td>
</tr>
</tbody>
</table>

ACNR • VOLUME 7 NUMBER 6 • JANUARY/FEBRUARY 2008 | 31
Another future threat is a renewed interest in the sub-consultant grade. With a new potential “bulge” of trainees likely to complete training around 2012, our job is to ensure that consultant positions are available for them, and that they are not forced into non-consultant positions.

A Knowledge based assessment is very likely to be introduced for those of us in the new curriculum but increasing costs, and the potential for the exam to be branded and sold to non-specialist trainees has led to disquiet. There is not an easy solution to this problem – summative assessment of knowledge is required by PMETB, although the best format and style of this is unclear.

For the ABNT to be effective and representative, it is essential that trainees remain engaged and involved. Information is available on the ABN website; and there is now a trainees forum that allows us to disseminate important information and encourages online discussion of contentious issues. The email addresses of all committee members and regional representatives are also available. It is important that the ABN office has a note of your most up-to-date email addresses to allow for rapid and cost-effective communication with you. Registrars will soon be emailed as part of the British Neurological Surveillance Unit (BNSU). Finally, please, encourage FY1 & 2 and ST1 and 2 to become members of the ABN.

Daniel Blackburn, Andrew Kelso and Biba Stanton
(On behalf of the ABNT)

The True Cost of Brain Injury
Headway, the Brain Injury Association’s 2007 Conference and Exhibition
October, 2007; Stratford-upon-Avon, UK.

Baroness Susan Greenfield was the big draw for this gathering of professionals concerned with the needs of the brain-injured. Her speech ‘The Future of Neuro-protection: the Benefits of Early Prevention’, highlighted on conference flyers, was the finale to a day filled with passionate discussion.

‘Passion’ was the word used by two personal injury solicitors from different firms in the exhibition. Asked what had drawn them into this specialist area, each cited the impact in their family lives of someone with brain injury.

Dr Andy Eynon’s opening discussion ‘Is Specialist Intensive Care Really Worth It?’ got people exercised about the relative lack of investment in acute specialist care, which would save vast sums of money in the long run. For example, survivors of head and spinal trauma, stroke, intracranial infections whose ‘care is time-dependent’, may have reduced chances of appropriate rehabilitation and re-entry into the labour market, if they have not received specialist management in the critical early days. It is possible to focus on numbers of critical care beds available across the 27 specialist neuroscience centres in England and Wales (Feb. 2006, total adult beds 206). A Paediatric Neuroscience Nurse Consultant gave me a much smaller number available for children, and endorsed Eynon’s main argument, ‘It is the logistical reorganisation that is difficult’ within the NHS.

This is despite recent governmental attention to neurological conditions (e.g. the National Service Framework for long term conditions, ‘Mending Hearts and Brains’, and the NICE guidelines for head injury management). NICE recommended ‘that all patients with severe head injury are managed at a specialist centre’. Eynon called for ‘rapid access to specialist units, aggressive treatment and early rehabilitation close to the patient’s home’. It is not just a matter of more money, but careful and well-informed planning. (Eynon is Doctor of Neurosciences ICU at the Wessex Neurological Centre. Their evidence is in ‘Intensive Care Medicine’ 2007 33 Suppl 2 S 130).

Ron Payne provided a stark illustration of the individual and social costs incurred by the lack of targeted critical care and the uneven distribution of facilities for longer-term management. Heather, his wife, a brain injury survivor, sent apologies for not being well enough to speak that day. Slides of their lives before and after Heather’s brain injury enhanced Ron’s narrative. Both had worked in local government, enjoying healthy active lives and travelling. Seventy-two hours after a trip abroad Heather had an extensive DVT and intervention was difficult. She was deemed unlikely to survive. However, within a few days, Ron noticed some signs of response (flickering eyes, smiling), but not until Heather squeezed his hand, Ron said, was the care plan altered to support her accordingly. Several months later, Heather came home, and life became even more difficult through the lack of joined-up services. Few facilities were available in their area of Staffordshire, such as hydrotherapy, something Heather had benefited from in the early days. Ron described the strain of living with someone doubly incontinent, whose bedding he changed in the night, living in a downstairs room with insufficient space for two single beds and the necessary hoist. He felt unsupported and dealt with his stress by drinking. However, Heather’s sister discovered a specialist centre in Northumbria where ‘they have absolutely everything you could wish for: physio-, OT and neuropsychology for both of us’. They relocated. When asked about his own health, Ron replied, ‘My health has deteriorated to the same degree as Heather’s has improved, but the cost is worth it, to get my Heather back’.

Each personal story surrounding brain injury is unique. But the aims of helping, whether it be through rehabilitation of physiological function or the capacity to rejoin the labour market, as well as the long term financial management, need to be considered in the round and across the whole of society. Alister Berry, Clinical Neuropsychologist, reported from Rehab UK on an evaluated project in South Tyneside. District Judge Gordon Ashton, Deputy Master, the Court of Protection, gave a compassionate and erudite outline of the implications of the Mental Capacity Act, including recent changes in the Court of Protection procedures and aims. His emphasis on consulting the protected person about the broadest aspects of their personal welfare, beyond basic financial management, was very welcome. Other speakers discussed ‘the Money Minefield’ of state benefits (Gillian Solly, of Davies and Partners) as well as the question of whether those should replace damages (Elizabeth-Anne Gumble QC and Henry Whitcomb QC).

This combination of speakers gave a kaleidoscopic view of the many and various costs of brain injury, to individuals, their families, work places, and society in general, over the decades that many survive.

After all this intensely concerned applied discussion it was a treat to be entertained and educated by Susan Greenfield, using a battery of engaging slides together with a very clear description of her research at the molecular level with possible neuroprotective agents (apoptosis inhibitors, anti excitoxic agents; neurotrophic factors; ion channel modulators). She proposed to talk ‘controversially about the brain stem area’: ‘if there is damage in this vulnerable hub’, citing as examples, PD and Alzheimer’s, ‘although they arise from different areas embryologically they ’retain the ability to grow again’ and what is necessary in early brain development may be damaging in later life. Sharing her question-raising approach to experimentation, she demonstrated her renowned skills as communicator of scientific ideas.

For further information on the 2008 Headway Conference and Exhibition, please contact Rachel Broughton on 0115240800 or email eventsandconferences@headway.org.uk.

For further information on Headway, please visit www.headway.org.uk

Richenda Power PhD,
Writer,
member of the London Freelance Branch of the NUJ.
Stroke and Nutrition Conference
5 March, 2008, Missenden, UK
E. Audrey Callum, accala@01bucks.ac.uk
T. 01494 522141, Ext: 2397
Where’s the Evidence Introduction to Evaluated Resources
6-8 February, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
36th Annual INS Meeting
6-9 February, 2008, Waikoloa, Hawaii, USA
International Neuropsychological Society
T. +1 (641) 263-4200, F. +1 (641) 263-4866, E. ins@iou.edu
Normal Gait Revised
7 February, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
MR Paediatric Study Day
11 February, 2008, Manchester, UK
T. 01276 696474, E. sara.cowen@siemens.com
Stroke Management & Care – Semester 2
11 February, 2008 start
E. accala@01bucks.ac.uk
T. 01494 522 141 Ext 2397
Learning, Memory and Cognitive Function.
Mechanisms, Neuro, Pathology and Therapeutics
10-12 February, 2008, Valencia, Spain
T. +34 96 197 4670, E. cate@uva.es, www.foundationuva.es/cate@uva
Putting Rehabilitation into Practice – Primary
11 February, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
10th Annual National Dementias
E. ann@marlbankgroup.com
Rehabilitation: How do we know it is effective?
T. 020 7647 3538 E. rehabilitation@rcn.org.uk
RCN International Rehabilitation and Intermediate Care Nursing Forum conference
T. 020 7647 3538 E. rehabilitation@rcn.org.uk
Posture & Balance in Neurological Conditions - Upper Limb, Qualified Staff
13-14 February, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
4th Annual Update Symposium Series on Clinical Neurology and Neurophysiology
18-19 February, 2008, Tel Aviv, Israel
ISAS International Seminars, POB 574, Jerusalem 91004, Israel
T. 972-2-520574, F. 972-2-520505, E. register@isas.co.il
www.neurophysiology-symposium.org/ Insight Workshop
22-23 February, 2008, London, UK
E. enquiries@braintraining.co.uk
www.braintraining.co.uk
Stroke Management & Care – Semester 2
25 February, 2008 start
E. accala@01bucks.ac.uk
T. 01494 522 141 Ext 2397
Neurology Upper Limb for Occupational Therapists
30 Jan 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
BISWG South Wales & West Country Regional Meeting
31 January, 2008, Cardiff, UK
T. 02920 228275, E. kate.coles@hughjames.com
2nd International Congress on Gait & Mental Function
1-3 February, 2008, Amsterdam, The Netherlands
www.kenes.com/gait/
Reflexive Practice
4-5 February, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
South West Brain Injury Social Work Regional Group
5 February, 2008, venue tbc
T. 01752 272304, E. jackie.burt@plymouth.gov.uk
Explaining Pain with Lorimer Moseley
30 March, 2008, Worcester, UK
E. info@phyisicns.co.uk
Practical Neurology Study Days
31 March – 1 April, 2008, London, UK
T. 0207 722 7979, F. 020 7831 0448, E. courses@ch.ac.uk
April
Report Writing for Doctors and Consultants
2 April, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
Witness Skills for Doctors and Consultants
3 April, 2008, Derby, UK
E. ncore@derbyhospitals.nhs.uk
www.ncore.org.uk
T. 01332 254679
60th Annual Meeting of the American Academy of Neurology
5-12 April, 2008, Chicago, USA
T. +1 6519527717, E. membersservice@aan.com
The Psychosocial Burden of Epilepsy: Amoderating impact
6-8 April, 2008, Oxford, UK
E. isabella@eppur.org.uk, www.epilepsyresearch.org
Sexuality and Acquired Brain Injury Workshop
7 April, 2008, London, UK
T. 0208 780 4530, E. psimonson@rh.org.uk
The International Brain Injury Association’s 7th World Congress on Brain Injury
9-12 April, 2008, Lisbon, Portugal
E. mjtipsberad@fast.com, or T. 001 703 960-6500
World Parkinson’s Disease Day conference
10 April, 2008, Cairo, Egypt
E. lizzie@epda.com
The British Pain Society’s 2008 Annual Scientific Meeting
15-18 April, Liverpool, UK
www.britishpainsociety.org/meet_futureas.htm
Mobility On The Edge International seminar
16-18 April, 2008, Oswestry, UK
Karen Edwards, E. karen.edwards@ysh.nhs.uk
T. 01691 404531
2nd National Treating Schizophrenia Conference
24-25 April, 2008, London, UK
E. ann@marlbankgroup.com
Nicotinic Receptors
23-26 April, 2008, Cambridge, UK
http://firstcontact.hinxton.wellcome.ac.uk
BISWG Brain Injury and Mental Health - National Conference in Cardiff
24 April, 2008, Cardiff, UK
T. 0208 780 4530, E. psimonson@rh.org.uk
Applied Bioinformatics & Public Health Microbiology
27- 29 April, 2008, Cambridge, UK
http://firstcontact.hinxton.wellcome.ac.uk
May
13th European Congress of Clinical Neurophysiology
3-8 May, 2008, Istanbul, Turkey
www.ecc2008.org/
9th European Congress of Neuroophthalmology
8-10 May, 2008, Athens, Greece
E. iman@umac.uva.nl, T. 30-2-107-257-693, F. 30-2-107-2532
6th Workshop of the International Society for Musculoskeletal and Neural Interactions
8-11 May, 2008, Cologne, Germany
E. info@mes-cbmi.org, Mme Yvonne Bertz, T. 00 49-30-078-9590, E. 49-3-07-008-895-111
V Scientific Symposium of Polish Society for Neurological Rehabilitation
9-10 May, 2008, TarnówSKie, Poland
www.rrtt.pl
National Brain Science Writing Prize 2008
Launching 10 March 2008 in Brain Awareness Week
Do you have a passion for brains?
Could you write a newspaper-style article celebrating the amazing world of brain science?

At-Bristol, the European Dana Alliance for the Brain and the British Neuroscience Association have joined forces with Focus magazine to find the best brain communicators in the country!

Visit the website for details of prizes and how to enter.
www.youramazingbrain.org

Brain Awareness Week
10 – 16 March 2008

Every March the European Dana Alliance for the Brain (EDAB) coordinates Brain Awareness Week, a major collaboration celebrating the wonders of the brain and brain research through hundreds of public events worldwide.

EDAB is an organisation that is committed to enhancing the public’s understanding of why brain research is so important.

To find out more, visit our website www.edab.net or contact EDAB by phone on +44 20 7019 4914, or by email enquiries@edab.net

www.fundacioncac.es/catedrasg
Eighteenth Meeting of the European Neurological Society

June 7–11, 2008

Nice, France

20th Anniversary of the first ENS Meeting in Nice
Neurology: Learning, knowledge, progress and the future

Key symposia:
- Coma and locked-in syndrome
- Behavioural disorders and dementia
- Autoimmune disorders of the nervous system
- Multiple sclerosis: when to start a treatment and which treatment
- Transient ischemic attacks: diagnosis and management

The congress programme includes interactive case presentations, 23 teaching courses, workshops organised by the ENS subcommittees and selected scientific sessions in the form of oral sessions, poster sessions (guided poster walks) and satellite symposia.

Abstract Submission Deadline: January 31, 2008
Early Registration Deadline: April 8, 2008

For further information please contact:
Administrative Secretariat:
18th ENS 2008, c/o AKM Congress Service
P.O. Box, CH-4005 Basel / Switzerland
Phone +41 61 686 77 11  Fax +41 61 686 77 88  E-mail info@akm.ch

www.ensinfo.com
MULTIPLE SCLEROSIS: A few bad lymphocytes spread all over the brain in multiple sclerosis

Open any neurology textbook and you will find multiple sclerosis described as a condition where CD4+ T lymphocytes invade the brain where they encounter a brain protein (perhaps “MBP”, myelin basic protein) and so they set up pockets of inflammation (“plaques”). If it is an up-to-date textbook, it may go on to say that “antigen-specific therapy” is the holy grail of multiple sclerosis therapeutics; that is to say, those techniques which identify and eliminate, say, MBP-reactive CD4+ T cells are the answer. This German-Austria study has upset all that. It is a study of the lymphocytes found in 19 plaques and in normal appearing brain from the post-mortem brains of just four people with multiple sclerosis. In particular, the group analysed the T-cell receptor gene rearrangements, using “TCR spectratyping”. This is a clever way of asking: what antigen do these lymphocytes recognise? (For the techno-nerds, 325 semi-nested PCR reactions were performed to sequence 800 Vbeta-NDN-Jbeta combinations at the single-cell level). There were four key findings:

1. In the brains of each patient, the lymphocyte population mainly consisted of just one or two clones which had considerably expanded. In other words, only a few antigens drive the abnormal immune response in each person with multiple sclerosis.

2. These distinct T-cell clones were present throughout the brain, both in plaques and in normal appearing white matter. So, the immune attack of multiple sclerosis is far less focal than we thought.

3. The lymphocyte clones from one patient’s brain were completely different to those of another brain. So, the antigens driving multiple sclerosis are “private” and specific for each individual. (However, a little caveat here is that a study of just four brains is hardly epidemiology!)

4. At least some of the T cell clones are CD8+ cells. So we need to pay attention to this cell group as well in multiple sclerosis therapies…..

Unfortunately, Junker’s technology does not actually tell us the identity of the antigens recognised by the T cell clones. Nonetheless, this is all seriously bad news for those academics and companies who are busy devising “antigen-specific therapies” on the assumption that one antigen (MBP, PLP and a host of other candidates) drives multiple sclerosis in all individuals. It turns out to be all rather more complicated.….. Ah well…. – AJC


EPILEPSY: and osteoporosis

Anyone who has been to the Chalfont Centre for Epilepsy knows that it is a special place. A rural idyll fulfilling the 19th century dream of care for the severe epileptic. A cluster of houses and a workshop for simple work for the severe epileptic. A small number of patients had never reached maximum bone mass and the younger the patient at onset of epilepsy, the worse the problem. Of 208 patients, 31% were osteopenic and 37% osteoporotic. All but one had started AED’s community, but they nevertheless have some lessons to teach us. Of 208 patients, 31% were osteopenic and 37% osteoporotic. All but one had started AED’s


HUNTINGTON’S DISEASE: potential quantitative biomarker in peripheral blood or not?

Up to now, no single therapy has been shown to delay disease onset or slow the progression of Huntington’s disease, in part because it is hard to know how one can easily measure such an effect. One solution could be quantitative biomarkers in peripheral blood. In this recent study, Runne et al have measured mRNAs in peripheral blood cells and evaluated their utility as a potential transcriptomic biomarker. The authors have performed microarray gene expression profiling analysis on lymphocyte samples collected from 12 moderate stage HD patients and 10 controls using Affymetrix U133 Human Genome 1.0 Plus array for gene expression. Surprisingly, despite the authors initial hypothesis that neuroinflammation is an established and progressive facet of HD pathology and their expectation that related transcriptional change would be identified in HD blood, no HD-related statistical changes were detected on a single gene testing basis. This is in contrast to a previous study which had shown that transcriptomic changes in blood were a robust biomarker in tracking HD progression. The authors suggest that this difference may be due to varied subpopulations within HD. If this is the case, then there are real concerns as to whether any biomarkers may be useful in HD, until there is a better understanding of disease heterogeneity. – CA


HEADACHE: Brainstem dysfunction in chronic migraine

The term “transformed migraine” used for chronic migraine accurately reflects the mystery surrounding its aetiology. In attempting to unravel central mechanisms in pathogenesis, this study investigated cortical excitability in chronic migraineurs and controls. Magnetic suppression of visual perceptual accuracy was measured. Positron emission tomography (PET) was used to see if there were correlated areas of excitation or inhibition. In patients with chronic migraine the study found reduced visual suppression and therefore a lack of inhibition in these patients. This correlated with PET studies in the same patients showing increased metabolism in the pons and right temporal cortex but reduced metabolism in the medial frontal cortex. The authors suggest that cortical excitability is raised in chronic migraine patients and point to evidence that patients with episodic migraine have similar but less marked changes. This correlates with the clinical observation of heightened sensitivity in migraine patients to external, particularly visual, stimuli. The finding must be treated with caution as the numbers studied are small, but they are intriguing. It seems likely that modulation of central excitatory and inhibitory pathways are one component of the intricate complex of peripheral and central changes in migraine. – HAL

Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and Positron Emission Tomography studies. CEPHALALGIA 2007;47:996-1003.

NEURAL TRANSPLANTATION: Taking neural crest stem cells to new heights

Adult neurogenesis has been a hot topic for some time, but really in the context of the brain. A recent publication from a group in Spain led by Lopez-Barneo and colleagues has now taken the topic to the carotid body. In this structure they have shown how:

a. expansion or shrinkage of the carotid body as it experiences hypoxia and
normal oxygen tensions.

b. that it contains BrDU positive cells that can be grown in vitro to produce neurospheres.

c. that these cells can express tyrosine hydroxylase and release dopamine, and

d. the source of these neuroprogenitors is a GFAP positive sustentacular cell derived from the neural crest. Thus we have evidence for a neural crest derived precursor cell that is capable of dividing into dopaminergic releasing progeny and so could be considered for use in Parkinson's disease. Indeed this group have recently experimented with using carotid body transplants in patients with Parkinson's disease. There was variable clinical benefit with little evidence of dopamine cellular survival in the grafted striatum at least on PET scanning. Nevertheless these studies do suggest that more ethically neutral and practically accessible tissue sources may be available for patients with this common neurodegenerative disorder. – RAB

Pardal R, Ortega-Saenz P, Duran R, Lopez-Barnejo I. 
Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. CELL


PARKINSON’S DISEASE: smoking, coffee and NSAIDs

The effects of smoking, coffee drinking and use of nonsteroidal anti-inflammatory drugs (NSAIDs) on developing PD have been examined individually but their joint possibly synergistic effects have not. In this recent study, Payami et al have studied 1,186 Parkinson’s patients and 928 controls to quantify any associations of these factors in different combinations. Standardised questionnaires were used throughout the study where detailed questions on smoking, drinking and over the counter (OTC) and prescription (Rx) NSAIDs habits were recorded. Results show that smoking at any time was associated with 23% reduction in risk of Parkinson’s disease and current smoking with a 55% reduction in risk. Risk seemed to decrease with increasing smoking pack-years (P<0.001), where the lowest risk (56%) was reported for patients with a > 40 pack-year history, regardless of age, sex or family history. High coffee consumption was associated with a 25% risk reduction with a significant dose-response gradient (P<0.001). The coffee effect was more pronounced in men than in women with the coffee dose response relationship being highly significant in men but not in women. For NSAIDs the results revealed a 19% reduction but no obvious dose–response effect. When family history was taken into account, it revealed that the risk reduction for PD was only evident in nonfamilial PD cases. The effects of smoking, amount of coffee intake and use of NSAIDs appeared to be independent and cumulative. This collection of data on such a large number of patients is clearly a major achievement and represents a powerful data set though the fact that individuals were asked to reflect on their habits covering a lifetime of customs such as smoking, coffee drinking and consumption of NSAIDs is problematic. Nevertheless when interactions are further probed, it can be seen that the combined risks of any two factors is lower than the risks associated with the individual factors with the combination of all three factors giving the lowest risk profile. The additive effects of all three factors give a highly significant reduction of developing PD by as much as 87% although whether they are due to direct protective effects remains to be explored by further studies. Till then we might want to start consuming more coffee! – CA


Alasdair Coles, Cambridge University; Andrew Larner, Walton Centre, Liverpool; Mark Manford, Addenbrooke’s Hospital, Cambridge and Bedford Hospitals; Wendy Phillips, Addenbrooke’s Hospital, Cambridge; Robert Redfern, Morriston Hospital, Swansea; Aliie Turton, University of Bristol.

Episenta: Controlled release sodium valproate that’s easy to swallow

The issue of compliance of AEDs has been raised by a number of studies indicating that poor compliance in patients with epilepsy can relate to increased seizure frequency. However, some tablets, particularly controlled release ones, can be rather large and many patients experience swallowing difficulties. The use of syrup presentations may help, but they are not very palatable and are more expensive. Whereas some formulations may be difficult to swallow, Episenta capsules or sachets can be opened and the minitablets sprinkled onto soft foods such as yoghurt or taken with drinks. Episenta aims to be the patient friendly option. The capsules and sachets contain many minitablets each of which is a prolonged delivery unit to reliably deliver sodium valproate as a once-a-day treatment to help enhance acceptability to patients and improve compliance. Episenta can be taken either before, during or after meals without any affect on absorption as the minitablets pass through the pylorus independent of food and do not get retained in the stomach to cause gastric irritation. This makes it easier for the patient to fit the medication to their lifestyle. There are good pharmaceutical reasons why Episenta should be the presentation of choice when requiring a prolonged release sodium valproate, but there are also sound financial reasons. Episenta is bioequivalent to Epilim Chrono and yet the NHS price is about 25% less. Episenta even costs less than standard Epilim tablets. Using Episenta ensures significant savings to the drug budget. For more information T. 01892-600930.
**New Ti series – a central resource for live cell imaging**

Nikon launched the Ti Series recently. Available in three distinct models, the Ti range combines rapid system speed with a flexible design incorporating capabilities including: confocal, TIRF, fluorescence and Nikon’s patented Perfect Focus System (PFS) into one powerful integrated unit set to expand and advance current live cell imaging research.

Offering faster acquisition times and unparalleled levels of accuracy, the Ti platform has been designed in close collaboration with the industry’s leading cell biologists and presents the field with a versatile new tool. The Ti-E is now the first microscope system to incorporate optimised synchronised switching improving total system performance. All component parts are integrated within a central hub and intelligently controlled through Nikon’s NIS elements software. This enhances speed of operation, minimises component movement and improves experimental accuracy.

Complementing the range, the Ti-S and Ti-U derivatives are ideal for researchers requiring less advanced systems with a lower level of integration, and are specifically indicated for use in more routine laboratory work.

For more information see www.nikoninstruments.eu

**Zeiss sets new standard for zoom, magnification and resolution in stereomicroscopy**

Carl Zeiss has added a flagship stereomicroscope to its range with the launch of the SteREO Discovery.V20. The 20x zoom is the highest zoom factor and final magnification of any stereomicroscope available on the market. Thanks to the newly computed PlanApo S 2.3x objective, the SteREO Discovery.V20 also delivers the highest resolution in stereomicroscopy with 1000 Lp/mm, with a maximum magnification of 345x (eyepieces 10x).

“*The new microscope owes much of its exceptional optical performance to the CMO (common main objective) imaging system pioneered by Zeiss*," says Aubrey Lambert, Marketing Manager at Carl Zeiss UK. “*The 20x zoom range enables users to move seamlessly from a panoramic overview of an object to examining extremely small details without any time-consuming change of objectives. This is a significant benefit in automated workflow environments. Furthermore, the high final magnification of the SteREO Discovery.V20 permits three-dimensional observation of objects that, until now, could only be examined two-dimensionally with a traditional light microscope.**

The advanced design guarantees safe object manipulation, combining high magnification with generous working distances. Ergonomically, every microscope function can be controlled through SyCoP, which integrates the entire System Control Panel into a mouse-like controller. This allows intuitive control of the motorised zoom and focus, the illumination, and the real-time display of total magnification, object field, resolution, depth of field and Z position. A range of high-performance CMO lenses enables fine details to be visualised with outstanding contrast and in three dimensions.

For more information T. 01707 871 200, E. micro@zeiss.co.uk

---

**Study shows Topamax® provides sustained reduction in monthly migraine days for up to one year**

A new long-term study into migraine prevention published in The Lancet Neurology shows that patients who continued with Topamax® (topiramat) for migraine prophylaxis for up to a year experienced a sustained reduction in the number of migraine days per month, with significant associated benefits on quality of life measures.1 The study also found that there was a significant increase in the number of monthly migraine days following discontinuation of topiramat, however, the number did not return to pre-treatment levels.

The PROMPT (PROlonged Migraine Prevention with Topiramate) study was a 12-month, multicentre, double-blind, randomised, placebo-controlled study conducted to investigate the continued effectiveness of topiramat in reducing the number of migraine days beyond six months, compared with the impact of stopping treatment at six months. All patients received open-label Topamax for the first 6 months, and then were randomised to either continue Topamax or take placebo for the second 6 months in a double-blind design.

After 6 months of open-label topiramat treatment, the mean number of monthly migraine days fell significantly from 8.93 to 5.83, a reduction of 3 migraine days per month (p<0.0001). After 12 months, the reduction in the mean number of monthly migraine days seen during the first six months was maintained and remained almost unchanged in the group that continued on topiramat.

For more information T. 01494 567567.

---

**Guerney invests in onsite scanning facilities from Siemens**

Princess Elizabeth Hospital, Guernsey, has installed the SOMATOM Sensation 64 and MAGNETOM Avanto 1.5 scanner from Siemens Medical Solutions in its newly built scanning department. The installations will add permanent MR and CT capabilities to its in-house services and enhance its imaging, clinical and diagnostic capabilities.

To date patients have had to travel to Jersey or Southampton for their scans; in 2006 approximately 882 people were referred to off-island hospitals. With demand increasing, Princess Elizabeth Hospital needed to provide on-site scanning, imaging, clinical and diagnostic capabilities.

The new unit gives permanent access to state-of-the-art MRI and CT scanning equipment.

The combined products have the advantage of providing better imaging and staging processes. The high end MAGNETOM Avanto uses Total image matrix (TIM) technology, providing significant advantages in imaging, allowing a greater range in examinations. The scanner will be used to look at detailed images and the high resolution technology offers a new level of clarity. This allows early detection of abnormalities and decreases time to treatment.

It improves patient comfort and care, with the AudioComfort technology reducing noise encountered by patients by 97%. The high speed technology shortens the time to complete the scan and its innovative design gives the patient more room to relax.

For more information E. medmarketing.med.gb@siemens.com

---

**Reference**

SonoSite system excels in rheumatology and musculoskeletal imaging

Dr Philip Platt, Consultant Rheumatologist at the Freeman Hospital, Newcastle, relies on a SonoSite MicroMaxx® hand-carried ultrasound system to help diagnose patients, to assess treatment efficacy and to improve the accuracy of local injection treatments in both his rheumatology and sports injuries clinics. Dr Platt explained, “Ultrasound gives good diagnostic accuracy for musculoskeletal problems and I believe the patients get better care as a result.” Being able to scan while moving a joint around is a unique advantage of ultrasound particularly useful for soft tissue and tendon injuries and gives a whole new aspect that other imaging modalities just don’t provide.” For rheumatology, Dr Platt described a very significant application of ultrasound in monitoring the effective but expensive anti-TNF drug. “This relatively new drug works for many rheumatoid arthritis patients but not all. It is very important to identify which patients do or don’t benefit from treatment so they are not taking drugs inappropriately. One of the best ways to monitor the response is to use ultrasound to see whether inflammation has reduced.” He added, “The great advantage of these hand-carried systems is the time they save. They are easy to carry to different wards and hospital sites, and are ready to use in under 15 seconds. In contrast, pushing heavy cart-based systems around the hospital, waiting for lifts, trying to find space beside a patient’s bed, and then waiting for the machines to boot up is a real waste of time.”

For more information T. 01462 444 800, E. europe@sonosite.com, www.sonoosite.com

ABN Medal 2007

The ABN Medal is awarded annually to recognise outstanding contributions by British neurologists to the science or practice of neurology, or for contributions to the Association of British Neurologists. The 2007 award was made to Professor Richard Langton-Hewer at the recent ABN meeting, by ABN President Professor Graham Venables.

In his citation, Derick Wade notes that Professor Langton-Hewer was ahead of his time, practicing through his clinical activities principles that were at the time unusual, but that are now becoming mainstream. He was patient-centred when much of medical practice was still professionally driven and centred, and was ahead of his time in the collection and use of routine patient data. This was part of his insistence on generating and using evidence to support service development. He was concerned with the development and provision of clinical services. At the time this was not a popular view within the medical profession in general and within the ABN in particular. He was also ahead of his time in that he collaborated with other professions on an equal footing. He was truly committed to multi-disciplinary teams at a time when doctors still expected to lead and to be obeyed.

ABN Case Report winner

ACNR is delighted to sponsor the ABN Case Presentation Competition which is held at each ABN meeting. At the recent ABN in London, Dr John McHugh won the award for his Case Presentation “Startling new antibody in an old Irish jumper.” Dr McHugh’s case report also won the 2007 Royal Academy of Medicine in Ireland’s Registrar’s Prize in Neurology, which took place on Friday, November 23rd, at the Four Seasons Hotel, Ballsbridge, Dublin. See www.icrn.ie/education/rami_registrars_prize_in_neurology.501.html for an abstract of the case report.

£250,000 research grant awarded

The Oliver Zangwill Centre, based at the Princess of Wales Hospital in Ely, has just been awarded a major research grant of £250,000 by the NHS “Research for Patient Benefit” programme. This grant will help researchers at the Centre find out whether reminders delivered to patients with acquired brain injury via mobile phone text messaging can improve brain injured patients’ achievements in their day-to-day lives.

Dr Fergus Gracey, lead applicant for the grant said “We want to find out whether an alert, delivered via mobile phone text messaging, can improve patients’ with acquired brain injury achievements of tasks in their day-to-day lives. We also want to know whether such a service would help improve patients’ and carers’ emotional well being and stress. There is little research that tells us what helps patients in their day-to-day lives. We have evaluated the provision of a timed electronic alert reminding someone of what they need to do at a specific time, for example, ‘take medication’ at 6.00 pm, sent to the patient via a pager and shown this to be effective. We now provide this ‘Neuropage’ service nationally. However, not everything we do can be timed in this way and patients and relatives tell us they like to have space for flexibility and spontaneity in their lives.”

The findings from our research will be used to help develop our existing service and community rehabilitation provision in the region. As the intervention is delivered via mobile phone we have the potential to reach a large number of patients and carers more economically. We will share our findings with others to contribute to the development of clinical practice in rehabilitation.”
COPAXONE® (glatiramer acetate)

PRE-FILLED SYRINGE

PRESCRIBING INFORMATION

Presentation - Glatiramer acetate 20mg solution for injection in 1ml Pre-filled Syringe.

Indication - Reduction of frequency of relapses in relapsing-remitting multiple sclerosis in ambulatory patients who have had at least two relapses in the preceding two years before initiation of therapy. Dosage and administration - 20mg of glatiramer acetate (one pre-filled syringe) administered subcutaneously once daily. Children (<18 years) Not recommended. Elderly No specific data.

Long-term active

Date of preparation: October 2007 Code: C0807/428a

COPAXONE® (glatiramer acetate)

PRE-FILLED SYRINGE

PRESCRIBING INFORMATION

Presentation - Glatiramer acetate 20mg solution for injection in 1ml Pre-filled Syringe. Indication - Reduction of frequency of relapses in relapsing-remitting multiple sclerosis in ambulatory patients who have had at least two relapses in the preceding two years before initiation of therapy. Dosage and administration - 20mg of glatiramer acetate (one pre-filled syringe) administered subcutaneously once daily. Children (<18 years) Not recommended. Elderly No specific data.

Indication

- Reduction of frequency of relapses in relapsing-remitting multiple sclerosis in ambulatory patients who have had at least two relapses in the preceding two years before initiation of therapy.

Dosage and administration

- 20mg of glatiramer acetate (one pre-filled syringe) administered subcutaneously once daily. Children (<18 years) Not recommended. Elderly No specific data.

Contra-indications

- Known allergy to glatiramer acetate or mannitol (excipient). Pregnancy. Special warnings and precautions - Sub-cutaneous use only. Initiation to be supervised by neurologist or experienced physician. Supervise first self-injection and for 30 minutes after. One or more of vasodilatation, chest pain, dyspnoea, palpitations or tachycardia may occur within minutes after injection. These generally resolve spontaneously after a short time. If severe, treat symptomatically. Caution in patients with pre-existing cardiac disorders and review such patients regularly. Rarely, convulsions and/or anaphylactic or allergic reactions. Rarely, hypersensitivity (bronchospasm, anaphylaxis or urticaria). If severe, treat appropriately and discontinue Copaxone. Interactions - No formal evaluation. Increased incidence of injection-site reactions with concurrent corticosteroids. Theoretical potential to affect distribution of protein-bound drugs, therefore concomitant use of these should be monitored. Pregnancy and lactation - Not to be used in pregnancy. Consider contraceptive cover. No data on excretion in human milk. Undesirable effects - Injection site reactions (erythema, pain, mass, pruritus, oedema, inflammation, hypersensitivity, lipodystrophy). An immediate post-injection reaction (one or more of vasodilatation, chest pain, dyspnoea, palpitation, tachycardia) may occur within minutes, reported at least once by 41% of patients receiving Copaxone compared to 20% of patients receiving placebo. >1%: Nausea, anxiety, rash, sweating, chills, face oedema, syncope, vomiting, lymphadenopathy, oedema, nervousness, tremor, herpes simplex, skin benign neoplasm, eye disorder, vaginal moniliasis. Rarely: Anaphylactoid reactions, convulsions, shifts in white blood cell counts, elevated liver enzymes (with no evidence of clinical significance) and skin necrosis at injection sites. Please refer to the SPC for a full list of adverse events. Overdose - Monitor, treat symptomatically. Pharmaceutical Precautions - Store Copaxone in refrigerator (2ºC to 8ºC). If the pre-filled syringes cannot be stored in a refrigerator, they can be stored at room temperature (15ºC to 25ºC) once for up to one month. Legal Category - POM. Package Quantity and Basic NHS Cost - 28 pre-filled syringes of Copaxone: £545.59. Product Licence Number - 10921/0023. Further Information - Further medical information available on request from Teva Pharmaceuticals Limited, The Gate House, Gatehouse Way, Aylesbury, Bucks, HP19 8DB Date of Preparation - September 2007.

Information about adverse event reporting can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Teva Pharmaceuticals Ltd on telephone number: 01296 779758.